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 It is imperative for pork producers to understand the effects of disease on commercial 
production, including its impact on pig performance, carcass quality and net returns. Due to 
production losses caused by health challenges, historically, most research has focused on 
prevention and/or eradication, and has been conducted under carefully controlled conditions 
where the etiology of one or possibly 2 diseases can be carefully investigated. This leaves a 
particular gap in information on the impact of naturally occurring disease that is often complex 
and multi-factorial in nature.  As one example, there is some limited data that suggests that 
health challenged pigs must be fed diets with lower concentrations of synthetic AA and higher 
concentrations of soybean meal (SBM). Therefore, the overall objectives of this thesis were to 
assess the productivity and economic importance of naturally occurring health challenges (HC) 
under commercial conditions and to investigate a possible benefit of higher levels of dietary 
SBM in HC pigs. Three commercial grow-finish facilities located in central Iowa were each 
populated with 936 weaned crossbred pigs [Cambrough female (PIC 1050) × DNA600 terminal 
sire] each. Pigs were allotted based on sex and visual BW distribution across pen and within 
barn. Thirty-four d post weaning (13.1 ± 0.2 kg), pigs were placed on test until harvest (130.5 ± 
1.4 kg). Barns were characterized as low challenge health (LCh), moderate challenge health 
(MCh) or high challenge health (HCh) according to diagnostic assessments and other health 
indicators. In chapter 2, each barn represented an independent study. Four dietary treatments 
were applied within experiment to contain one of 4 levels of SBM ranging from high SBM 
(HSBM) to high synthetic AA (HSAA). In addition to measuring ADG, ADF and G:F, blood 
samples were collected to determine serum levels of isoflavones, a class of phytoestrogens 
thought to possibly improve pig health when they are challenged with bacterial or viral 
 xii 
pathogens. In the LCh experiment, ADG was improved (P < 0.05) in pigs fed the HSBM and 
moderate SBM (MSBM) diets. Improvements in G:F were observed in pigs fed the HSBM and 
MSBM treatments in the LCh and HCh experiments (P < 0.05), and tended to be improved in the 
MCh experiment (P < 0.10). Final BW was lower on the HSAA diet in all experiments (P < 
0.05). In the MCh experiment, reduced levels of all serum isoflavones in the HSAA treatment 
was associated with reduced final BW and a tendency to decrease G:F (P < 0.10). Unfortunately, 
inconsistent amino acid levels, some of which were estimated to be below requirement, prevent 
the drawing of any conclusions from this dataset. In chapter 3, the observed HC was considered 
the applied treatment. Average daily gain, ADFI and G:F were reduced and mortality increased 
with an increased HC (P < 0.05). Decreased ADG increased days to achieve market BW, by 10 
and 15 d in the MCh and HCh treatments compared with LCh, respectively (P < 0.05). No 
differences were observed for percent lean, loin depth or fat depth (P > 0.10). In order to assess 
the economic impact of the HC, the results of this experiment were applied to a 2,400 grow-
finish barn using one of two economic models, encompassing the two main marketing methods 
used by U.S. pig producers, namely fixed-weight and fixed-time. Production losses attributed to 
disease severity were between $9.47 and $23.27 U.S dollars (USD)/pig marketed at fixed-weight 
or between $12.61 and $25.27 USD/pig marketed at fixed-time, depending on feed costs and 
market hog prices. More work is necessary to evaluate the usage of SBM as an immune 
modulator in grow-finish pigs.  Nonetheless, the economic impact of disease clearly 








There are a variety of diseases that influence pork production, each providing their own 
challenges to the industry. Porcine reproductive and respiratory syndrome virus (PRRSV) and 
influenza type A virus of swine (IAV-S) are two of the most economically challenging diseases, 
playing an important role in all stages of pig production. These diseases tend to spread quickly in 
densely populated pig areas and are followed by increased mortality, morbidity and reduced 
growth rates resulting in financial losses to pig producers.  
 A great deal of research has been focused on soy isoflavones, mainly in humans, as a 
means to decrease the incidence and severity of disease. Unfortunately, a majority of the 
mechanistic research has been in a variety of in vitro tissues and diseases with different 
isoflavones at different inclusion rates, making it difficult to draw conclusions on these 
phytoestrogens. Soybeans are known to have naturally high levels of isoflavones; the hypothesis 
is that dietary soy could provide protective effects against diseases in humans and animals. 
However, some isoflavone research has been directed at pigs as a way to minimize the effects of 
the PRRS virus.  Very little published research has addressed the impact of soybean meal 
contributing positive effects found in in pigs.   
 This review will provide insight into the negative impact of PRRSV and influenza on 
swine production. These prevalent diseases have proven to be economically important for many 
years. Moreover, this review will focus on the proposed mechanisms of soy isoflavones in the 
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event of a viral infection. Finally, it will try to assess the use of isoflavones and dietary soybean 
meal to mitigate this negative impact caused by PRRSV.  
 
Porcine reproductive and respiratory syndrome virus (PRRSV) 
 In 1987, a “new” disease spread throughout the U.S. pork industry, characterized by 
severe reproductive losses, reduced growth rates, respiratory disease and high mortality (Butler 
et al., 2014). It wasn’t until 1991 when the cause of the disease was determined to be an 
unidentifiable single stranded RNA virus (Terpstra et al., 1991). Originally termed ‘mystery pig 
disease,’ this virus was later called porcine reproductive and respiratory syndrome virus 
(PRRSV) due to the highly distinguishable clinical symptoms. Since the 1980’s, PRRSV has 
become endemic around the world, categorizing it as one of the most economically important 
diseases affecting the pig industry (Zimmerman et al., 2012). 
 
PRRS virus replication  
The PRRS virus primarily targets pulmonary alveolar macrophages; however it can infect 
other immune cells including monocytes and dendritic cells (Thacker et al., 1998; 
Thanawongnuwech et al., 2000; Loving et al., 2015). Pulmonary alveolar macrophages and 
pulmonary intravascular macrophages have been described as the main cell types to support 
replication of the PRRS virus (Thanawongnuwech et al., 1997b; 2000) (Fig 1.1). The PRRS virus 
enters the target cell by standard clathrin-mediated endocytosis, requiring the CD163 receptor on 
the host cell for internalization (Lunney et al., 2016). Following transcription and translation of 
the viral DNA it is packaged into a nucleocapsid from budding of the smooth intracellular 
membranes and the new virion is then released from the cell by exocytosis (Lunney et al., 2016). 
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Viral replication generally takes 9-12 hours (Pol et al., 1997). The PRRS virus has been detected 
in lymph nodes, tonsils, heart, thymus, peyers patch, spleen, kidney, liver, adrenal gland, lungs 
and brain (Halbur et al., 1995a,b; 1996a,b; Rossow et al., 1996; Thanawongnuwech et al., 
1997b). However, PRRS virus levels are greatest in the lungs and lymph nodes (Zimmerman et 
al., 2012).  
 
Effect of PRRSV on immune function 
There are three lines of defense that make up the innate immune system: physical 
barriers, chemical barriers and immune cells. These barriers work to protect the body from 
infections, including viral infections. The innate immune system also functions to elicit an 
adaptive immune response in the event that other lines of defense were not successful in 
preventing an infection. The adaptive immune systems functions to eliminate and protect against 
that specific pathogen in the future. While many viruses will cause effective stimulation of the 
immune system, the PRRS virus does not; rather it has been associated with immune modulation 
and slowed viral clearance (Albina et al., 1998; Van Reeth et al., 1999; Renukaradhya et al., 
2010). This includes cell apoptosis, suppression of natural killer cells (NK) and macrophages and 
reduced cytokine secretion ( Zimmerman et al., 2012; Lunney et al., 2016). 
Cell apoptosis occurs not only in virus-infected cells but also to uninfected bystander 
cells (Sirinarumitr et al., 1998). This apoptosis occurs mainly in the lungs and lymph nodes and 
is thought to be the reason for the reduction in alveolar macrophages and circulating 
lymphocytes and monocytes in the event of a PRRSV infection (Sirinarumitr et al., 1998). The 
mechanism by which the PRRS virus induces apoptosis of bystander cells is unknown 
(Zimmerman et al., 2012). However, this decrease in immune cells may explain why PRRSV 
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infected pigs are more susceptible to secondary infections (Loula, 1991; Thanawongnuwech et 
al., 1997a; Zimmerman et al., 2012). 
 Natural killer cells (NK) provide antiviral defense, by secreting cytokines and killing 
infected cells (Dwivedi et al., 2011). Pigs experimentally infected with PRRSV showed a 50% 
reduction in NK cell killing function two days following the infection (Dwivedi et al., 2011). 
This suggests that the decrease in NK function allowed for the PRRS virus to continue infecting 
and replicating in other cells.  
Cytokines play an important role in the innate immune system by directing the 
mechanisms needed to prevent or decrease the invasion of pathogens. The PRRS virus causes 
significant reductions in innate cytokines when compared to other viral infection (Van Reeth et 
al., 1999). Decreasing cytokine levels will delay and diminish the activity of adaptive immunity 
(Lunney et al., 2016). When secreted cytokines can have positive and negative effects including 
leukocyte recruitment, reduction of viral replication, pulmonary edema, fever, lethargy and 
anorexia (Zimmerman et al., 2012).  
 
Clinical symptoms of PRRSV 
 While there is extensive variation in clinical symptoms associated with PRRSV, the 
ability of the virus to produce chronic and persistent infections in pigs has proven to be its key 
feature (Zimmerman et al., 2012; Butler et al., 2014). A herd can experience a PRRSV infection 
for as little as 10-12 weeks or as long as 4-6 months (Loula, 1991). Breeding herds will 
experience reproductive failure as a classic sign of PPRSV, including abortions and increased 
dead and weak born pigs ( Loula, 1991; Zimmerman et al., 2012; Butler et al., 2014). Pre-
weaning, pigs will experience rapid breathing, lethargy and high mortality and morbidity rates 
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(Loula, 1991). While in the nursery and growing phase, pigs will have suppressed growth rates, 
lethargy, rapid breathing, increased rectal temperatures and increased mortality following an 
infection ( Loula, 1991; Holtkamp et al., 2013; Rochell et al., 2015; Schweer, 2015 ). Disease 
severity will depend on many factors including viral strain, immune status, host susceptibility, 
concurrent infections and management factors, which can result in symptoms ranging from 
asymptomatic to detrimental (Zimmerman et al., 2012; Butler et al., 2014). It is important to note 
that a PRRSV infection will result in pigs becoming more susceptible to other viral or bacterial 
diseases that can exacerbate symptoms resulting in increased mortality (Loula, 1991; 
Zimmerman et al., 2012; Holtkamp et al., 2013).  
 
Economic importance of PRRSV 
 The decrease in growth rate and number of unmarketable pigs has resulted in PRRSV 
being categorized as an economically important disease. Holtkamp et al. (2013) estimated that a 
PRRSV infection is responsible for production losses of $663.91 million annually or $4.67 for 
every full value pig marketed in the United States.  Additionally, the biosecurity and health costs 
were estimated to be $477.79 million annually (Holtkamp et al., 2013). While the majority of the 
economic losses are attributed to production losses, a PRRSV infection will dramatically 
increase the input costs for health and biosecurity, as described by Holtkamp et al. (2013).  
 
Transmission of the PRRS virus  
 The negative effect of PRRSV on net returns has stimulated efforts to better understand 
how producers can more effectively characterize and control the virus. Porcine reproductive and 
respiratory syndrome virus is easily transmitted by direct or indirect contact (i.e. fomites) (Pileri 
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and Mateu, 2016). The PRRS virus is secreted in nasal secretions, saliva, urine, feces, mammary 
gland secretions and semen ( Swenson,  1994; Pirtle and Beran, 1996; Wills et al., 1997; Kang et 
al., 2010; Olsen et al., 2013). This makes on-farm exposure a frequent source of transmission, 
making biosecurity critical for disease control. 
 
Influenza type A virus of swine (IAV-S) 
 Influenza is a historically significant disease that was first recognized in pigs in 1918 in 
both the United States and Europe during the Spanish flu pandemic (Van Reeth et al., 2012). 
While this virus plays an important role in human and animal health alike, this review will focus 
on the impact of influenza on the U.S. swine industry.  
 
Influenza virus replication 
 The influenza virus predominantly targets the epithelial cells that line the respiratory tract 
from nasal mucosa to the alveoli (Janke, 2014). Hemagglutinin (HA) is a protein on the surface 
of the influenza virus that interacts with the sialic acid residues on the host cell surface (Basler 
and Aguilar, 2008). Hemagglutinin is necessary for the virus to attach to the host cell, be 
internalized and for intracellular interaction with endosomal membranes in the host cell to occur 
(Janke, 2014) (Fig 1.2). Once the host cell has been invaded by the virus, transcription of the 
viral mRNA will occur in the nucleus of the host cell (Janke, 2014).Viral polymerase complex 
and viral nucleoprotein (NP) are needed to synthesize viral RNA (Basler and Aguilar, 2008). 
Following transportation to the cytoplasm, translation of viral proteins occurs in the cytoplasm 
(Basler and Aguilar, 2008). The viral ribonucleoprotein particles (RNPs) assemble at the plasma 
membrane of the host cell allowing for the formation and release of a new virus particle (Basler 
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and Aguilar, 2008). The severity of the influenza virus is directly related to the ability of the 
virus to replicate and spread to new cells (Basler and Aguilar, 2008).   
 
Effect of influenza type A virus on immune function 
 Influenza is predominantly a respiratory disease that causes significant cellular damage in 
the respiratory tract. This damage can be attributed to destruction of infected cells by necrosis 
and apoptosis and cytokine release by the immune system and infected cells. Necrosis occurs by 
invasion of the influenza virus into respiratory epithelial cells, resulting in total cell lysis (Janke, 
2014). Due to cells rupturing, cytokines are released, causing an inflammatory response (Janke, 
2014). This can occur within 20 to 40 hours post infection (Janke, 2014). Infected cells will go 
through apoptosis, which has been described as a host defense mechanism to reduce viral spread 
and decreasing inflammation (Janke, 2014). 
 A viral infection of influenza will also result in cytokine response. Infected respiratory 
epithelial cells will produce type 1 interferon (IFN) which inhibits viral replication and infection 
to nearby cells and stimulates other pro-inflammatory cytokines (García-Sastre and Biron, 2006; 
Oldstone et al., 2013). Endothelial cells release tumor necrosis factor (TNF) – a, interleukin (IL) 
– 1 and IL – 6, bringing leukocytes to the site of injury (Janke, 2014). Unfortunately, cytokines 
can have adverse effects. Tumor necrosis factor – a can cause bronchial constriction and 
hyperactivity (Janke, 2014). Type 1 interferon – a and IL – 6 can systemically induce fever and 
cause the liver to produce acute phase proteins (Barbé et al., 2010; Pomorska-Mól et al., 2012). 
 Surface proteins will signal natural killer cells (NK), neutrophils and macrophages to the 
infected area (Janke, 2014). These innate immune cells work to clear the virus and infected cells 
from the site of injury.  
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Unfortunately, this is not a perfect system because in an attempt assist in viral clearance, 
cytokines can inadvertently cause damage to the cells in the respiratory tract (Janke, 2014). 
Severe infections are generally correlated with high levels of cytokines (Janke, 2014).   
 
Clinical symptoms of influenza type A virus 
 Clinical symptoms of the influenza virus can exhibit great variation from mild respiratory 
distress to severe dyspnea (Janke, 2014). Classically, swine influenza is characterized by fever, 
anorexia, lethargy, labored rapid breathing, and can be accompanied with a cough (Van Reeth et 
al., 2012). These clinical signs will typically result in high morbidity - up to 100% - and low 
mortality (Van Reeth et al., 2012). Symptom severity will largely be dependent on immune 
status, environment, viral strain and age (Vincent et al., 2008; Van Reeth et al., 2012). These 
symptoms can be intensified in the event of a co-infection with another virus or bacteria, much 
like the PRRS virus  (Van Reeth et al., 2012; Janke, 2014). However, the virulence of the 
influenza virus is dependent on the ability of the virus to enter a host cell, replicate, exit and 
spread to new cells (Basler and Aguilar, 2008). Type A influenza viruses are the only influenza 
viruses that can infect pigs (Janke, 2014).  
While there are no economic values applied to a swine influenza infection, it is 
considered an economically important disease, attributed to decreased growth rates resulting in 
increased days to market (Kothalawala et al., 2006).  
 
Transmission of the influenza virus  
 Swine influenza is readily shed in saliva and nasal secretions (Kothalawala et al., 2006). 
Shedding can begin to occur as soon as 24 hours after an infection (Kothalawala et al., 2006). 
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Similar to the PRRS virus, the influenza virus is spread by direct contact or contact with fomites 
(Tellier, 2006). Pigs are considered “mixing vessels” for influenza, meaning they have the ability 
to contract influenza viruses from different species (i.e. avian and human) (Van Reeth et al., 
2012). Due to the influenza virus possessing a segmented genome, confections can lead to re-
assortment of the viral genes (Basler and Aguilar, 2008). Pigs play an important role in this virus 
re-assortment, causing altered epidemiology of the influenza virus in pigs (Van Reeth et al., 
2012). The ability of the virus to so readily re-assort causes new challenges for swine producers 
today, even 100 years after it was first recognized in the United States.  
 
Disease surveillance  
 There are numerous diseases that influence modern hog production; unfortunately, many 
of them play a sizeable role in the economic return of a production system. Maintaining a 
continuous flow of information about these diseases in production systems is needed to support 
herd health activities and make effective production decisions (Olsen et al., 2013). However, 
production level surveillance is generally limited due to economic or technical constraints of the 
producer (Kittawornrat et al., 2010; Olsen et al., 2013). Relatively new, oral fluid sampling 
provides an alternative to collecting individual animal samples, eliminating some of the technical 
constraints that previously limited disease surveillance (Kittawornrat et al., 2010). Both influenza 
and PRRSV can be detected in oral fluids, allowing for a non-invasive technique to monitor 
these diseases ( Prickett et al., 2008; Detmer et al., 2011). Prickett et al. (2008) suggested that 
sampling in 2-4 week intervals is appropriate for the surveillance of PRRSV.  Surveillance can 




 Soybean meal is a main component of swine diets in the midwestern United States. 
Soybean meal provides protein, phosphorus, amino acids and biologically active components, 
including isoflavones. Isoflavones, which are classified as phytoestrogens, are naturally 
occurring compounds found in legumes, that structurally resemble 17β-Estradiol (Fig. 1.3) 
(Knight and Eden, 1996). Originally identified in clover by Bennetts et al. (1946), causing 
infertility in sheep, they are now being studied for the potential to have a positive effect on 
disease. There are three main isoflavones that are found in large amounts in soybeans: daidzein, 
genistein and glycitein (Barnes et al., 2000). However genistein is the most prominent 
(Lamartinere et al., 2002). These isoflavones are understood to exhibit antioxidant, anti-
inflammatory, anti-viral, anti-mutagenic and estrogen-like activities through a variety of 
mechanisms (Greiner et al., 2001a; Miadoková et al., 2002; McClain et al., 2007; Ryan-Borchers 
et al., 2007; Scarpato et al., 2008; Valsecchi et al., 2008; Barbosa et al., 2011).  
Isoflavones are present in soybeans in a β-glycoside structure; however these are not 
bioavailable, unless the glycoside group is removed (Omoni and Aluko, 2005). The gut 
microflora can remove the glycoside group via β-glycosidases, converting the β-glycoside 
structure to the aglycone structure ( Xu et al., 1995; Izumi et al., 2000; Setchell, 2000; Andres et 
al., 2009). It is important to note that the intestinal microflora influence isoflavone 
bioavailability, resulting in differences among individuals and species ( Xu et al., 1995; Omoni 
and Aluko, 2005).  Greiner et al. (1999) hypothesized that absorption in the gastrointestinal tract 
likely occurs by active absorption, while Sfakianos et al. (1997) suggested that it is passive.  
However, this mechanism is not well defined and may be dependent on the relative 
hydrophobicity of these compounds (Birt et al., 2001). Once absorbed, isoflavones are 
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glucuronidated or undergo sulfation, in intestinal epithelium prior to being released into the 
blood circulation or in the liver (Sfakianos et al., 1997). Once in circulation, isoflavones can be 
sent to different tissues for use or be eliminated in the urine ( Lundh, 1995; Chen and Donovan, 
2004; Chen et al., 2005).   
 A large majority of the published research on isoflavones has focused on humans, 
proposing benefits against chronic diseases including coronary heart disease and a variety of 
cancers (Munro et al., 2003).  Isoflavones have also exhibited an assortment of antiviral 
properties; however, much of this research has been conducted in vitro and its relevance in vivo 
remains uncertain (Andres et al., 2009). It is hypothesized that the antiviral activity of 
isoflavones is due to a combination of modulating effect of both the viral particle and host cell 
(Andres et al., 2009). A review article by Andres et al. (2009), assessed the impact of soy 
isoflavones on viral infections. Suggesting that isoflavones appear to have mainly inhibition 
effects (Fig. 1.4). Described mechanisms include: inhibiting virus binding, inhibiting tyrosine 
kinase activity, inhibition of tyrosine phosphorylation of glycoprotein E, inhibition of viral gene 
expression and protein function, inhibition of phosphorylation of viral polypeptides, inhibition of 
ATF-2 and CREB (transcription factors) phosphorylation, inhibition of NF-κB induction and 
inhibition of TNF-α secretion (Akiyama et al., 1987; Yura et al., 1993; Dangoria et al., 1996; 
Hayashi et al., 1997; Li et al., 2000; Robin et al., 2001; Akula et al., 2002; Pelkmans et al., 2002; 
Kubo et al., 2003; Sharma-walia et al., 2004; Evers et al., 2005; Kim et al., 2006; Andres et al., 
2007; Stantchev et al., 2007; Vela et al., 2008). However, conclusions are not easily drawn, as 
these studies are performed on different viruses, in different tissues (mainly in vitro) and at 
different isoflavone concentrations.  
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 The initial research on isoflavones and health challenged pigs was performed by Greiner 
et al. (2001a,b) on the effect of genistein and daidzein in the event of a PRRS virus challenge. 
Genistein linearly reduced serum virus concentrations, reduced serum INF, increased α1- 
acylglycoprotein (AGP) in times of high serum viral concentrations and linearly increased spleen 
weight, which indicated increased B-cell production (Greiner et al., 2001a). She also reported 
increased gain and feed intake during times of high serum viral concentrations; however this was 
not seen when viral concentrations were reduced (Greiner et al., 2001a). A regression analysis 
revealed that reductions in serum virus was associated with improved daily gain, suggesting that 
supplemented genistein can improve gain by minimizing serum viral concentrations (Greiner et 
al., 2001a).  Greiner et al. (2001a) concluded that feeding genistein prior to inoculating the pigs 
with PRRSV helped the animals to resist the virus and/or inhibit viral replication and that 
genistein aided in the pig’s ability to fight off the viral infection by reducing the virus’s ability to 
replicate, acting as an immune modulator. In Griener’s daidzein experiment, supplementation of 
daidzein did not change serum viral concentrations or AGP; however the low and high daidzein 
diets had greater INF during times of high viral load and spleen weight was increased, but no 
change in thymus weight was observed (Greiner et al., 2001b). Similar to the genistein 
experiment, daidzein improved daily gain and feed intake during the time the pigs experienced a 
high viral load (Greiner et al., 2001b). While daidzein did not alter the rate of virus elimination, 
it did improve pig growth during time of high viremia (Greiner et al., 2001b). In a more recent 
study, by Smith et al. (2017), no improvements in growth performance, viral load, total T-cell 
count or rectal temperatures with isoflavone supplementation were reported. However, 
hematocrit concentrations increased, neutrophils decreased and T-helper cells increased in pigs 
fed the isoflavone diet (Smith et al., 2017). This suggests a potential benefit to adaptive 
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immunity (Smith et al., 2017). Collectively these studies indicate that supplemented isoflavones 
have the potential to be immune modifiers in a pig model, by decreasing PRRSV viral 
concentrations, assisting the immune system and/or improving growth performance. 
 
The impact of soybean meal on disease challenged pigs 
 Finding ways to decrease the negative influence of a health challenge is the current focus 
of many research programs. The use of isoflavones found in soybeans has been hypothesized to 
decrease the impact of a health challenge in pigs ( Greiner et al., 2001a,b; Johnston et al., 2010; 
Rocha et al., 2013; Rochell et al., 2015; Fiene et al., 2016; Moran et al., 2016; Smith et al., 
2017). This hypothesis could potentially allow swine producers to feed higher dietary soybean 
meal as an immunomodualtory strategy in the event of a health challenge.  
 A majority of the published research on dietary soybean meal employed in the event of 
health challenge is inconsistent. Johnston et al. (2010) reported that pigs fed high soybean meal 
(HSBM) had 9% better gain, were 7.7% more efficient and had 10.6% greater carcass gain in 
comparison to the pigs fed the low soybean meal (LSBM) treatment, in the event of a PRRSV 
and porcine circovirus (PCV) infection. Rochell et al. (2015) reported greater final body weight 
for pigs that received the HSBM treatment in comparison to the LSBM treatment. 
Inconclusively, other experiments reported no overall difference in body weights, ADG, ADFI or 
G:F in pigs infected with a PRRS virus challenge ( Rocha et al., 2013; Rochell et al., 2015; 
Moran et al., 2016;).  
Moran et al. (2016) saw no effect on PRRS viral load with increased dietary soybean 
meal, while Rochell et al. (2015) reported reduced viral load at 14 DPI when pigs received the 
HSBM diet. Other health parameters reported suggest that while growth performance may not be 
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impacted, increased dietary soybean meal helped to minimize the immune stress that the infected 
pigs experienced. Rocha et al. (2013) reported that rectal temperatures were lowered on 3, 5 and 
7 DPI for pigs fed the HSBM in comparison with those fed LSBM; this corresponded with the 
HSBM treatment having better G:F than the LSBM diet at week 1 post challenge. However, 
Rochell et al. (2015) saw no differences in rectal temperatures between the high and low soybean 
meal diets. However, Rochell et al. (2015) did report reduced serum concentrations of 
inflammatory biomarkers (haptiglobin and TNF-a) on 3 and 14 DPI respectively, when pigs were 
fed the HSBM diet. Moran et al. (2016) reported a decrease of 24% in pigs removed for medical 
treatment with increased dietary soybean meal; this however, did not impact mortality or full 
value pigs. These results could suggest that feeding an increased level of soybean meal could 
help to minimize the immune stress experienced by the pigs.   
The experiments reported in this section of the review were all short studies or nursery 
length, suggesting that the positive impact of the observed health parameters could be translated 
to grow-finish pigs. Potential benefits could include reduction of labor and cost associated with 
treatments, minimized immune stress and maintained growth performance of pigs experiencing a 
health challenge.  
 
Conclusion  
 In order to be profitable in pork production, a certain level of health must be maintained. 
Porcine reproductive and respiratory syndrome virus and IAV-S are two of the most 
economically important diseases to the swine industry as they can increase production inputs and 
decrease margins. To reduce the production losses that are attributed to a PRRSV and IAV-S 
challenge, finding ways to maintain growth performance is imperative. A better understanding of 
 15 
soy isoflavones and soybean meal as immune modulators in the event of a PRRSV and IAV-S 
challenge can assist in decreasing the production losses associated with these health challenges. 
A better understanding of how these diseases impede profitability will create a more accurate 
representation of how pork producers manage and care for their animals in times of disease 
challenge. This review indicates that data are needed to understand the current production losses 
attributed to PRRSV and IAV-S challenge and how soybean meal (i.e. soy isoflavones) can be 
utilized to mitigate these production and profitability losses. 
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Figure 1.3. Chemical structure of human estrogen, 17β-Estradiol, the phytoestrogen compound, 



























Figure 1.4. Antiviral mechanisms of action of isoflavones and related compounds 
This diagram summarizes the various steps in virus-host cell interactions (dotted lines and 
italicized script). The flavonoid-mediated inhibition of virus infectivity and propagation is 
represented by solid lines. Isoflavones and related compounds have been shown to affect virus 
binding, entry and replication, viral protein synthesis and assembly of the glycoprotein complex, 
as well as TNF-α secretions and induction of transcription factors. Each mechanism of action is 












THE IMPACT OF A HEALTH CHALLENGE ON GROW-FINISH PIG GROWTH 
PERFORMANCE AND CARCASS CHARACTERISTICS AS INFLUENCED BY 





Isoflavones are naturally occurring compounds found in soybeans, soy products and 
legumes that have been identified to have a positive effect on disease. The objective of this 
experiment was to assess the growth and carcass performance of pigs experiencing a naturally 
occurring health challenge (HC) when fed SBM at different levels in their diets. Three 1,000 pig 
wean-finish facilities, located in Iowa, were populated with 936 wean crossbred pigs 
[Cambrough female (PIC 1050) × DNA600 terminal sire] each. Pigs were allotted based on sex 
and visual observation to ensure a similar BW distribution across pens. Pigs were placed on site 
at weaning until reaching 34 d post weaning (13.1 ± 0.2 kg), pigs remained on test until the end 
of the market phase (130.5 ± 1.4 kg). Each barn was characterized by the overall HC 
experienced, each representing an independent study. Overall, diagnostic assessments of oral 
fluid were the main characterization tool and were supplemented with other indicators of health, 
including mortality, morbidity, daily observation and medication treatment criteria. Experiments 
were characterized in relevance to each other as low challenge health (LCh), moderate challenge 
health (MCh) and high challenge health (HCh). Four dietary treatments were developed to 
contain a titrated level of SBM, ranging from high SBM (HSBM) to high synthetic AA (HSAA), 
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with two intermediate programs between the two extremes, namely moderate SBM (MSBM) and 
moderate synthetic AA (MSAA). In the LCh experiment, ADG was improved (P < 0.05) in pigs 
fed the HSBM and MSBM diets. Improvements in G:F on the HSBM and MSBM diet treatments 
were observed in the LCh and HCh experiments (P < 0.05), and tended to be improved in the 
MCh experiment (P > 0.05). Final BW was reduced in the HSAA diet in all experiments (P < 
0.05). In the MCh experiment, reduced levels of all sera isoflavones in the HSAA diet treatment 
could explain the reduced final BW and tendency to decrease G:F on this same diet treatment (P 
< 0.05). In the present experiments, improvements in final BW and G:F suggest that diets 
containing higher levels of SBM improved growth performance in the event of the observed HC. 
However, because of the inconsistent amino acid levels, some of which were estimated to be 
below requirement, it is not possible to relate animal performance to the proportion of SBM or 
synthetic AA in the diet. Thus, the objectives of this study were not accomplished. 
 
Introduction  
Porcine reproductive and respiratory syndrome virus (PRRSV) and influenza type A 
virus of swine (IAV-S) put substantial economic burdens on pork producers. During times of 
exposure to these respiratory diseases, pigs experience reductions in growth rate and increased 
morbidity and mortality (Holtkamp et al., 2013; Rochell et al., 2015). A main component of 
swine diets in the Midwestern U.S., soybean meal (SBM) provides protein, AA and biologically 
active components, including isoflavones.  The latter have been studied for the potential to have 
a positive effect on disease (Greiner et al., 2001a,b; Barbosa et al., 2011). 
A majority of the mechanistic research involving isoflavones has utilized a variety of in 
vitro tissues, a wide range of disease and different isoflavones at different inclusion rates, 
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making it difficult to draw conclusions about their benefit (Greiner et al., 2001a,b; Barbosa et al., 
2011). Greiner et al. (2001a,b) revealed that supplemented isoflavones have the potential to be 
immune modifiers in pigs by decreasing PRRS viral concentrations, assisting the immune system 
and/or improving growth performance. Inconsistent and limited published results leave 
unanswered questions about SBM’s contribution to the positive effects associated with the 
provision of beneficial outcomes from isoflavones in the event of a health challenge (Rochell et 
al., 2015; Johnston et al., 2010; Rocha et al., 2013; Moran et al., 2016; Fiene et al., 2016; Smith 
et al., 2017). 
The objective of this experiment was to assess the growth and carcass performance of 
pigs experiencing a naturally occurring health challenge (HC) when fed SBM at different levels 
in their diets. It was hypothesized that the diets containing higher levels of SBM would result in 
improved performance in the more health challenged pigs. A second objective was to determine 
if the isoflavone content of SBM would be correlated with the response to an increased health 
challenge. 
 
Materials and methods  
All experimental procedures adhered to guidelines for the ethical and humane use of 
animals for research and were approved by the Iowa State University Institutional Animal Care 






Animals, Housing, and Management 
Three wean-finish barns located in Iowa were each populated with 936 crossbred weaned 
pigs [Cambrough female (PIC 1050) × DNA600 terminal sire]. The 3 barns were identical in 
design, management and operation, and received identical diets during the course of this 
experiment. Each barn consisted of 46 identical pens (16.8 m2), equipped with fully slatted 
concrete floors, metal pen dividers and gates, 2 nipple water drinkers to provide water ad libitum 
throughout the experiment, and one 5-space stainless steel dry feeder. An automatic feed 
delivery system supplied specific amounts of specific diets to each pen (Feedlogic Corporation, 
Willmar, MN), ensuring ad libitum access to feed. Each barn was equipped with identical 
integrated ventilation controllers (Expert control, VPN 110, Automated Production Systems, 
Assumption, IL), which regulated exhaust fans, air inlets and heaters, thus maintaining a stable 
interior thermal environment.  
Pigs were received from two different sow sources, although both were of the same 
genetic origin.  One sow source was PRRSV naïve and the other was PRRSV positive. 
Thirty-six pens in each barn were filled with 26 weaned pigs at the time of allotment. 
Pigs were sorted by sex (16 barrow pens, 16 gilt pens and 4 mixed sex pens) and allotted based 
on visual observation of size. Each pen received 6 “small size,” 14 “medium size” and 6 “large 
size” pigs.  This procedure helped to ensure a similar BW distribution across pens within barn. 
Pigs were placed on site at weaning until 34 d post-weaning when they reached the initial BW of 
13.1 ± 0.2 kg. Pigs remained on test until they achieved a final BW of 130.1 ± 1.4 kg.   
All 3 barns were placed on the same feeding program, consisting of 8 dietary phases, all 
manufactured at the same feed mill (Mid State Milling, State Center, IA). Dietary phases were 
based on a feed budgeting system. All pigs were cared for and managed using identical 
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procedures applied by the same personnel and same veterinary services throughout the course of 
this study.  
 
Experimental Design and Diets  
Each barn was characterized by the overall HC experienced, each representing an 
independent study. Overall, diagnostic assessments of oral fluid were the main characterization 
tool and were supplemented with other indicators of health, including mortality, morbidity, daily 
observation and medication treatment. Oral fluids were collected at three time points (7, 63, 105 
d) over the duration of the experiments to monitor the HC. Mortality, morbidity and medication 
treatments were recorded daily to actively assess the degree of HC in each barn. Based on these 
characterization tools, experiments were characterized in comparative terms as low challenge 
health (LCh), moderate challenge health (MCh) and high challenge health (HCh). The disease 
challenges experienced by the barns were not imposed but rather occurred naturally, similar to 
what occurs in commercial production. The goal was to maintain a separate HC in each barn 
over the duration of the experiments.  
Four dietary treatments were developed to contain a titrated level of SBM, ranging from 
high SBM (HSBM) to high synthetic AA (HSAA) with two intermediate programs between the 
two extremes, namely moderate SBM (MSBM) and moderate synthetic AA (MSAA; Table 2.1). 
The HSAA diet contained the greatest amount of HCl-Lys, the MSAA diet contained 65% of the 
HCl-Lys in the HSAA diet, the MSBM diet contained 32% of the HCl-Lys in the HSAA diet, 
and the HSBM diet contained 0% HCl-Lys. Soybean meal was then added to the diets to meet 
the requirements of the essential AAs. Diets were formulated to meet or exceed NRC (2012) 
requirements and all contained 20% dried distiller’s grains (Table 2.2; 2.3). They were 
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isocaloric, with constant dietary SID Lys levels within each phase. Experimental diets contained 
a feed dye (Prince Corporation, Marshfield, WI) to ensure the correct diet was being fed to the 
pens assigned to each treatment. Titanium dioxide was added as a marker to phase 4 and phase 7 
diets at 0.04% to determine diet energy digestibility. All diets were made and delivered by Mid 
State Milling (State Center, Iowa). Diets were fed over an 8-phase feed budget regimen, so that 




A strict biosecurity protocol was established to avoid pathogen transfer between 
experiments as the barns were in very close proximity to one another (separated by only 15.2 m). 
Personnel were required to shower upon arrival at the farm, and movement was strictly limited to 
LCh followed by MCh followed by HCh. Boot washes with Virocid disinfectant (CID Lines, 
Belgium) were used upon entering and exiting each barn. Tyvex suits (Uline, Pleasant Prairie, 
WI.) were placed over coveralls, and boots were changed prior to entrance into each barn. No re-
entry into any barn was permitted within the same day unless the individual re-showered and put 
on clean coveralls. All tools remained in each assigned barn, unless necessary for use in another 
barn, in which case tools were disinfected before and after use. 
 
 Sample and data collection 
Pen BW (scale head, Chore-Time 100, Milford IN; load cells, Tru Test MP 800, 
Wellington, Auckland, New Zealand) and feed disappearance were determined at the start and 
end of the experiments, and used to calculate ADG, ADFI and G:F. Additionally, pigs in the 
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HCh and LCh experiments were individually tagged and weighed (Way Pig – Portable Litter 
Scale, mechanical, Raytec Manufacturing, Ephrata, PA; Individual pig scale – scale head, Digi-
Star stockweight 600, Fort Atkinson, WI; load cells, Digi – Star SW3300, Fort Atkinson, WI) to 
assess BW variation at the start of the experiments and at the start of the marketing phase, i.e., at 
the first marketing group. Date and BW were recorded for any pigs removed due to illness, 
injury or death. All pigs that started the experiment were accounted for as 1) pigs removed from 
the study due to morbidity, 2) mortality, 3) full value market pigs or 4) light-cull pigs (lights or 
culls sent to a secondary market).  
Pigs were marketed in 3 separate groups in order to achieve a targeted market weight of 
130 kg. Prior to marketing, all pigs received slap ham tattoos corresponding to their experiment 
and pen. Pigs were weighed at each marketing to collect market BW. The HCW, carcass yield, 
lean, fat depth and loin depth were collected at the harvest facilities (JBS, Marshalltown, IA). 
Research personnel attended the harvest to confirm the accuracy of the carcass data.  
Oral fluid samples were collected from six randomly selected pens within each barn on d 
7, 63 and 105 to assess the HC over the duration of the experiments. In a method described by 
Prickett et al. (2008), oral fluid samples were collected by hanging a cotton rope in the pen for 
approximately 30 minutes. Prior to contact with ropes, new gloves were worn to ensure samples 
were not contaminated. Oral fluid was harvested from the rope by placing the wet end of the rope 
into a new plastic bag, wringing out the rope and then transferring the oral fluid to a centrifuge 
tube. Oral fluid was transported on ice, centrifuged for 10 minutes at 1,000 RPM, and frozen at    
-80oC. Samples were analyzed by PCR for PRRSV and IAV-S at the Iowa State University 
Veterinary Diagnostics Laboratory (Ames, Iowa). 
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In twenty-one pens per experiment, one pig was individually tagged at the beginning of 
the experiment for serum collection to determine isoflavone concentration. Blood (27 mL) was 
collected by jugular venipuncture into serum tubes on d 14, 42, 70 and 98. Serum was transferred 
on ice, allowed to clot and centrifuged for 10 min at 1,000 RPM, and frozen at -80oC. Serum was 
prepared for isoflavone analyses using a modified procedure developed by Coward et al. (1996).  
Isoflavone concentration of daidzein, glycitein, genistein and total isoflavones was determined at 
the USDA-ARS National Center for Agriculture Utilization Research (Peroria, IL), using HPLC 
according to Berhow et al. (2006). 
At approximately 45 kg and 100 kg BW, fecal samples were collected from 29 pens in 
each of the LCh and HCh experiments. Titanium dioxide was added to the feed (0.04%) and fed 
for 5 d prior to fecal collection. Multiple fresh grab samples were collected for one day from 
each pen to ensure a representative sample was collected; corresponding feed samples were 
collected from each feeder in collection pens. Feed samples were homogenized within barn, 
dietary treatment and feeding phase. Fecal and feed samples were stored at -20oC, homogenized, 
dried and ground through a 1.0 mm screen (Wiley Mill 3379-K35, Thomas Scientific, 
Swedesboro, NJ) for future analysis.  
 
Chemical Analysis 
 Fecal and feed samples were assayed for DM and GE. The DM was determined by drying 
at 105oC until a constant weight was achieved. The GE was determined using an isoperibolic 
bomb calorimeter (model 6200; Parr Instrument Company, Moline, IL). Benzoic acid (6,318 kcal 
GE/kg; Parr Instrument Company) was used as the standard to calibrate the bomb calorimeter 
(6,318 ± 10 kcal/kg was determined). Titanium concentration in both feed and fecal samples was 
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determined according to the method described by Leone (1973).  All analyses were performed in 
duplicate. A maximum 1% CV was required for DM and GE, and 5% CV for titanium dioxide 
concentrations. Apparent total tract digestibility (ATTD) of GE and DM were calculated 
according to Oresanya et al. (2007). Feed samples were analyzed for AA at the University of 
Missouri-Columbia Agricultural Experiment Station Chemical Laboratories (Columbia, MO). 
 
Statistical Analysis 
UNIVARIATE (SAS Inst., Inc., Cary, NC) was used to determine equality of variances 
and to remove outliers, which were defined as observations beyond 3 standard deviations of the 
mean. Growth performance, carcass characteristics and ATTD data were analyzed using MIXED 
model methods (SAS Inst., Inc., Cary, NC) with pen as the experimental unit and fixed effects of 
treatment, sex and their 2-way interactions. Sera isoflavone concentration was analyzed using 
MIXED model methods (SAS Inst., Inc., Cary, NC) with pen as the experimental unit, collection 
time as repeated measure and fixed effects of treatment, sex and their 2-way interactions. 
Statistical significance was determined at P ≤ 0.05 and trends considered when 0.05 < P ≤ 0.10. 
 
Results 
Effect of soybean meal inclusion level on performance in a low challenge health (Exp. 1) 
The HSBM and MSBM treatments improved ADG and G:F (P < 0.05; Table 2.4) in 
comparison to the MSAA and HSAA diet treatments. There was a trend for the HSBM and 
MSBM diets to have the greatest final BW (P < 0.10). Dietary SBM did not affect ADFI or BW 
CV at d 0 (P > 0.10). There was an interaction of dietary SBM inclusion and sex for BW CV at d 
117, with the barrow pens similar across treatments. The mixed pens’ CVs were greatest in the 
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HSBM and HSAA diets while the gilt pens had the greatest BW CV in the MSBM diet (P < 
0.05). Market BW was significantly improved with increased dietary SBM inclusion (P < 0.05). 
This was translated to HCW, where the MSBM and HSBM diets had the greatest HCW in 
comparison to the MSAA and HSAA treatments (P < 0.05). However, no differences were 
observed for the main effect of SBM treatment on yield, lean, loin depth or fat depth (P > 0.10).  
Barrow pens had improved final BW, ADG, and ADFI in comparison to gilt pens, with 
the mixed pens similar to the barrow pens (P < 0.05). Gilt pens had better G:F in comparison to 
the barrow pens, with mixed pens intermediate between the two (P < 0.05). No differences of sex 
were observed for BW CV at d 0. Similar to final BW, barrow pens had improved market BW 
and HCW in comparison to gilt pens, with the mixed pens similar to the barrow pens (P < 0.05). 
Gilt pens were significantly leaner and had less fat depth in comparison to barrow pens, with the 
mixed pens intermediate between the two (P < 0.05). Barrow pens and gilt pens had greater yield 
than the mixed pens (P < 0.05). No differences were observed for the main effect of sex on loin 
depth (P > 0.10).  
 There were no differences in ATTD of DM or GE for SBM treatment or sex (P > 0.10; 
Table 2.5). Sera concentrations of genistein, daidzein and total isoflavones were significantly 
decreased over time (P < 0.05; Table 2.6). Sera concentration of glycitein was greatest at 63 d 
and least at 35 and 91 d (P < 0.05). No differences were observed for the main effect of SBM 
treatment or sex on sera isoflavone concentrations (P > 0.05).  
 
Effect of soybean meal inclusion level on moderate challenge health (Exp. 2) 
 Pigs fed the MSBM treatment had improved final BW in comparison to those fed HSBM 
and HSAA SBM treatments (P < 0.05; Table 2.7). There were no differences observed for ADG 
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or ADFI for the main effect of SBM treatment (P > 0.10). There was a trend for improved G:F in 
the HSBM and MSBM treatments (P < 0.10). Market BW was improved in pigs fed the HSBM, 
MSBM and the MSAA diets (P < 0.05). There was a trend for decreased HCW in the HSAA diet 
treatment (P < 0.10). No differences for the main effect of SBM treatment were observed in 
carcass yield, lean, loin depth or fat depth (P > 0.10).  
 Barrow pens had greater final BW than gilt pens, with mixed pens intermediate between 
the two (P < 0.05). Barrow pens had greater ADFI than gilt pens, with the mixed pens similar to 
the gilt pens (P < 0.05). However, gilt and mixed pens were more efficient than barrow pens (P < 
0.05). There were no differences for ADG for the main effect of sex (P > 0.05). Market BW and 
HCW was improved for barrow pens when compared to the gilt pens, with the mixed pens 
intermediate between the two (P < 0.05). Gilt pens were significantly leaner than barrow pens 
and had reduced fat depth (P < 0.05). No differences were observed for yield or loin depth for 
the main effect of sex (P > 0.10).  
 Sera concentrations of genistein, daidzein and total isoflavones were reduced at 63 d, in 
comparison to the other collection time points (P < 0.05; Table 2.8). Sera concentrations of 
glycitein were elevated at 91 d (P < 0.05). The HSAA treatment significantly reduced glycitein, 
genistein, daidzein and total isoflavones in comparison to the HSBM and MSBM treatments (P < 
0.05). No differences were observed for the main effect of sex on sera isoflavone concentrations 
(P > 0.10).  
 
Effect of soybean meal inclusion level on high challenge health (Exp. 3) 
 Final BW was improved in the MSBM and MSAA treatments in comparison to the 
HSAA treatment (P < 0.05; Table 2.9). No differences were observed for ADG, ADFI, BW CV 
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at d 0 or d 132 (P > 0.10). Feed efficiency was improved in the HSBM treatment (P < 0.05). The 
MSBM diet had the greatest market BW, in comparison to the HSAA treatment (P < 0.05). This 
difference in market BW was translated to HCW, with the MSBM diet having greater HCW than 
HSBM and HSAA (P < 0.05). There were no differences in yield, lean, loin depth or fat depth 
for the main effect of SBM treatment (P > 0.10).  
 Barrow pens had the greatest final BW, ADG, and ADFI in comparison to the gilt pens, 
with the mixed pens intermediate between the two (P < 0.05). Gilt pens however, were more 
efficient than barrow and mixed pens (P < 0.05). There were no differences in BW CV on d 0 or 
d 132 for the main effect of sex (P > 0.10). Barrow pens had improved market BW and HCW, 
when compared to the gilt and mixed pens (P < 0.05). Gilt pens were leaner and had less fat than 
barrow and mixed pens (P < 0.05). No differences were observed for yield or loin depth for the 
main effect of sex (P > 0.10). 
 There were no differences in the ATTD of DM or GE for the main effects of SBM 
treatment or sex (P > 0.10; Table 2.10). An interaction of SBM treatment over time showed 
MSAA and HSAA improved glycitein sera concentrations at 7 d (P < 0.05; Figure 2.1). At 63 d 
HSBM and HSAA improved glycitein sera concentrations; however, at 91 d, HSBM and MSBM 
improved glycitein sera concentrations. An interaction of SBM treatment over time revealed 
little difference between SBM treatment on 7 and 35 d for genistein. However, HSBM and 
HSAA improved genistein sera concentrations at 63 d and HSBM and MSBM improved 
genistein sera concentrations at 91 d (P < 0.05; Figure 2.2). Again, few differences were 
observed at 7 and 35 d between SBM treatments for total sera isoflavone concentrations. Similar 
to genistein, HSBM and HSAA improved concentrations of total sera isoflavones at 63 d while 
HSBM and MSBM improved concentrations at 91 d (P < 0.05; Figure 2.3).  No differences were 
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observed for sera daidzein concentrations for the main effects of time, SBM treatment or sex (P 
> 0.10; Table 2.11).  
 
Discussion 
In the event of a health challenge, growth performance will be influenced due to 
reductions in feed intake, muscle protein catabolism and diversion of necessary nutrients to 
support immune function (Williams 1997a,b,c; Huntley et al., 2017). In two experiments, 
Greiner et al. (2001a,b) concluded that supplemented isoflavones have the potential to be 
immune modifiers by decreasing PRRS viral concentrations, assisting the immune system, 
and/or improving growth performance in growing pigs. Isoflavones, which are classified as 
phytoestrogens, are naturally occurring compounds found in soybeans, soy products and other 
legumes that structurally resemble 17β-Estradiol (Knight and Eden, 1996). These biologically 
active compounds are understood to exhibit antioxidant, anti-inflammatory, anti-viral, and anti-
mutagenic properties through a variety of mechanisms (Greiner et al., 2001a; Miadoková et al., 
2002; Valsecchi et al., 2008). If this is true, swine producers should feed higher levels of dietary 
SBM as an immunomodulatory strategy in the event of a health challenge. While there are 
published abstracts to support this idea, only one full manuscript has been published by Rochell 
et al. (2015) to support this claim. Thus, the three concurrent experiments reported herein were 
conducted to evaluate the use of SBM as an immunomodulatory strategy in the event of a 
PRRSV and IAV-S co-challenge.  
There is a risk associated with comparing three experiments, since differences among the 
experiments could be due to factors other than those under investigation.  However, great care 
was taken to minimize the risk that any differences among the experiments, other than disease. 
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The 3 concurrent experiments were conducted in barns identical in design and construction, and 
located on the same physical site (Fig 2.4). They were managed on a day-to-day basis by the 
same person, were of the same genetic origin, and received the same dietary regime. Therefore, 
the design and operation of these experiments permitted comparison, although the authors 
recognize that this must be done with great care.  
Exposure to PRRSV and IAV-S will result in lethargy, reduced growth rates and 
increased mortality and morbidity in grow-finish pigs (Rochell et al., 2015; Schweer, 2015; 
Schweer et al., 2016). The pigs in all three experiments displayed classic clinical symptoms of 
PRRSV including lethargy and mortality (Rochell et al., 2015; Schweer, 2015). Evaluation of 
oral fluids by PCR revealed that pigs in all three experiments had been exposed to a primary 
PRRSV infection (Table 2.12). The HCh experiment had the greatest concentration of PRRSV 
genomic copies in oral fluid at d 7 and 63; at d 105 the MCh had the greatest concentration. Pigs 
in the HCh treatment were suspected of being infected with a secondary PRRSV strain, based on 
diagnostic testing results. However, due to the virus’s ability to mutate quickly, it is uncertain 
whether a second PRRSV detection was a mutation or a second lateral virus introduction into the 
environment from a different source. Oral fluid PCR found that the pigs in the MCh experiment 
contracted IAV-S (H1N2) by d 7, and both HCh and MCh experiments were diagnosed with 
IAV-S (H1N1) on d 63. Additionally, clinical symptoms of IAV-S, including anorexia, lethargy, 
labored breathing and a cough, were observed in the HCh and MCh experiments (Van Reeth et 
al., 2012). As the apparent HC increased, the number of individual medication treatments by 
injection was elevated (1,108, 2,335 and 3,415 in the LCh, MCh and HCh experiments, 
respectively). Furthermore, due to the rise in mortality from the LCh to MCh to HCh, there were 
reductions in pigs sold as full-value. The performance of animals in these three concurrent 
 46 
experiments represented three HCs and provided a very good platform for achieving the 
objectives previously identified.  
Greiner et al. (2001a;b) reported improved growth performance when supplementing soy 
isoflavones in the event of a PRRSV health challenge, a result not fully supported by this 
experiment, where an improvement in ADG in pigs fed the HSBM and MSBM diets was only 
observed in the LCh experiment. Johnston et al. (2010) reported a 9% improvement in ADG in a 
HSBM diet in the event of a PRRSV and PCV2 infection. Similar to other published work, no 
differences were observed for ADFI in any experiment (Rocha et al., 2013; Moran et al., 2016). 
Improvements in G:F on the HSBM and MSBM diet treatments, in all experiments, agrees with a 
10.6% improvement in G:F in a HSBM diet reported by Johnston et al. (2010). Final BW was 
reduced in the HSAA diet in all experiments; similarly, Rochell et al. (2015) observed pigs 
receiving a HSBM treatment had greater final BW than those on the LSBM treatment. Market 
BW and HCW were reduced in the HSAA diet treatment across all experiments. In the present 
experiments, improvements in final BW and G:F suggest that diets containing higher levels of 
SBM improved growth performance in the event of the observed HC. 
The diets containing greater levels of SBM would be expected to have greater levels of 
isoflavones; this was the case for total isoflavones. However, some individual isoflavones in the 
diets did not follow this same pattern but rather were inconsistent, perhaps due to their overall 
lower concentration.  
It would be expected that the dietary level of isoflavones would influence the sera 
concentration of isoflavones (Cook, 1998; Kuhn et al., 2004). In these experiments, sera 
isoflavone concentrations were impacted most significantly by the main effect of time due to the 
diets containing less SBM in later feeding phases. In the MCh experiment, reduced levels of all 
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sera isoflavones in the HSAA diet treatment could explain the reduced final BW and tendency to 
decrease G:F on this same diet treatment. Work published by Greiner et al. (2001a,b) revealed 
genistein linearly reduced serum virus concentrations and increased gain and feed intake during 
times of high serum viral concentrations, and that daidzein improved pig growth during times of 
high viremia. It is not clear why this trend was not observed in the HCh experiment. 
At the beginning of the trial, the dietary treatments were formulated to meet NRC (2012) 
requirements and to contain the same level of SID Lys. Upon AA analysis of complete diet 
samples, it was revealed that AA levels were not consistent, and some of the diets were deficient 
in some of the essential AA, including Lys, Thr, Met, Trp, TSAA and Ile. To better understand 
the AA composition of the dietary treatments, diets were back formulated on a total AA and SID 
AA basis, utilizing the NRC (2012) tables of ingredient composition (Table 2.13 – 2.16). Total 
and SID AA levels were calculated using the diet formulations, revealing that the level of AA in 
some of the diets were lower than expected (Table 2.2, 2.3). An explanation of how these 
calculations were carried out can be found in Appendix A. The revelation that some of the diets 
were deficient in one or more essential AA(s) concentration presents the strong possibility that 
the experiment was confounded by diet. 
To better understand what may have occurred to cause this discrepancy between expected 
and actual amino acid levels, a comprehensive evaluation of the diets was completed. To ensure 
data integrity, diet samples were sent to a second laboratory to re-analyze AA content. No 
differences were observed between the two laboratories, which allowed analytical error to be 
eliminated as a cause to diet differences. Soybean meal samples were obtained from the mill to 
analyze for AA content; while the analyzed SBM samples had slightly lower total AA levels than 
the NRC (2012), this was also ruled out as an explanation for this problem. Using the diet 
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formulations and the assayed SBM values, DDGS and HCl-Lys content were calculated to assess 
if any differences were observed for these individual ingredients; again, this was not the cause of 
the problem. The diets were then back formulated using the EvaPig program (Ajinomoto, Itasca, 
IL), since this database, not NRC (2012), was used in the initial diet formulations. Subtle 
differences were observed between EvaPig and the NRC (2012) for total AA content of 
ingredients and ingredient AA digestibility. Using the EvaPig program, diets were again back 
formulated (Tables. 2.17 – 2.20) which revealed that the diets appeared to be formulated on a 
constant Lys level but on a total, not an SID, basis. This can be seen by comparing the 
formulated Lys values on Tables 2.17 and 2.18 to the formulated composition of SID Lys on 
Tables 2.2 and Table 2.3. In any case, because of the inconsistent amino acid levels, some of 
which were estimated to be below requirement, it is not possible to relate animal performance to 
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 Table 2.1. Ingredient composition (as-fed basis) of the experimental diets  
Ingredient, % 
Phase 11 Phase 22 Phase 33 Phase 44 Phase 55 Phase 66 Phase 77 Phase 88 
HSBM HSAA HSBM HSAA HSBM HSAA HSBM HSAA HSBM HSAA HSBM HSAA HSBM HSAA HSBM HSAA 
Corn 26.71 47.85 33.36 51.48 36.50 52.54 41.89 59.70 47.95 66.22 54.54 71.50 56.50 73.98 58.18 74.30 
Soybean meal, 47.5% 46.17 26.50 40.28 23.41 37.91 23.00 32.50 16.00 26.00 9.00 19.50 3.50 17.50 1.00 16.00 1.00 
Dried distillers grains 
with solubles 
20.00 20.00 19.93 19.93 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 - - - - 
Dried distillers grains 
with no solubles 
- - - - - - - - - - - - 20.00 20.00 20.00 20.00 
Choice white grease 5.29 2.78 4.22 2.11 4.04 2.19 4.10 2.00 4.59 2.50 4.50 2.54 4.57 2.57 4.52 2.72 
Limestone 1.03 1.06 1.05 1.11 1.00 1.09 0.95 1.04 0.92 1.00 0.91 0.99 0.88 0.94 0.85 0.92 
Salt 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35 035 0.35 0.25 0.25 
Monocalcium     
phosphate  
0.25 0.25 0.25 0.25 - - - - - - 0.00 0.25 0.00 0.25 - - 
VTM premix9 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 
Copper sulfate 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
MXE10 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
L-Lysine HCl 0.00 0.62 0.00 0.53 0.00 0.47 0.00 0.52 0.00 0.54 0.00 0.50 0.00 0.52 0.00 0.46 
MHA11 0.00 0.16 0.00 0.09 0.00 0.02 0.00 0.01 - - - - - - - - 
L-Threonine 0.00 0.16 0.00 0.11 0.00 0.09 0.00 0.11 0.00 0.12 0.00 0.09 0.00 0.11 0.00 0.07 
L-Tryptophan 0.00 0.02 0.00 0.01 - - 0.00 0.02 0.00 0.03 0.00 0.03 0.00 0.05 0.00 0.03 
Feed dye12 0.00 0.05 0.00 0.05 0.00 0.05 0.00 0.05 0.00 0.05 0.00 0.05 0.00 0.05 0.00 0.05 
CTC 100 - - 0.20 0.20 - - - - - - - - - - - - 
Denagard 10 - - 0.18 0.18 - - - - - - - - - - - - 
High synthetic amino acids (HSAA) diet contained the greatest amount of HCL-Lys, moderate synthetic amino acids (MSAA) diet contained 65% of the HCl-Lys in the HSAA diet, moderate soybean 
meal (SBM) (MSBM) diet contained 32% of the HCl-Lys in the HSAA diet, and high SBM(HSBM) diet contained 0% HCl-Lys 
1Feed budget called for 9 kg per pig (15-21 kg) 
2Feed budget called for 9 kg per pig (21-27 kg) 
3Feed budget called for 36 kg per pig (27-46 kg) 
4Feed budget called for 36 kg per pig (46-63 kg) 
5Feed budget called for 36 kg per pig to (63-78 kg) 
6Feed budget called for 36 kg per pig (78-90 kg) 
7Feed budget called for 54 kg per pig to (90-109 kg) 
8 Feed budget called for 82 kg per pig to (110-130 kg) 
9Vitamin and mineral premix provided per kg of complete diet: vitamin A, 3,638 IU; vitamin D, 992 IU; vitamin E, 17 IU; menadione, 1.3 mg; niacin, 16.5 mg; riboflavin, 3.3 mg; pantothenic acid, 10.7 
mg; vitamin B12, 0.017 mg; Zn, 67.0 mg as zinc sulfate; Fe, 61.0 mg as ferrous sulfate; Mn, 15.3 mg as manganous oxide; Cu, 6.2 mg as TBCC; I, 0.3 mg as EDDI; Se, 0.3 mg as sodium selenite.   
10456 FTU phytase per kg of diet 
11Methionine hydroxy analog  







 Table 2.2. Nutrient composition (as-fed basis) of experimental diets Phase 1-4 
 Phase 1 Phase 2 Phase 3 Phase 4 
Item  HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA 
Formulated composition1                  
 ME, Mcal/kg 3.43 3.41 3.40 3.39 3.38 3.37 3.36 3.35 3.39 3.38 3.37 3.36 3.41 3.40 3.39 3.38 
 Calcium, % 0.63 0.61 0.61 0.60 6.62 0.61 0.61 0.60 0.55 0.55 0.55 0.54 0.52 0.50 0.50 0.50 
 Available phosphorus, %   0.43 0.43 0.42 0.41 0.43 0.42 0.41 0.40 0.37 0.36 0.36 0.35 0.36 0.36 0.35 0.34 
 Total phosphorus, % 0.60 0.58 0.56 0.52 0.58 0.56 0.53 0.50 0.52 0.49 0.47 0.45 0.49 0.47 0.44 0.42 
 Crude protein, % 28.37 26.45 24.62 21.52 26.20 24.28 22.17 20.28 25.25 23.51 21.75 20.03 23.14 21.20 19.27 17.39 
 SID Lysine, % 1.45 1.45 1.46 1.45 1.31 1.32 1.31 1.31 1.26 1.25 1.25 1.26 1.11 1.11 1.12 1.12 
 SID Threonine, % 0.98 0.91 0.88 0.88 0.91 0.84 0.79 0.79 0.88 0.81 0.76 0.76 0.80 0.73 0.69 0.69 
 SID Tryptophan, % 0.32 0.29 0.27 0.23 0.29 0.26 0.23 0.21 0.28 0.25 0.23 0.20 0.25 0.22 0.19 0.18 
 SID TSAA, % 0.89 0.84 0.84 0.84 0.84 0.79 0.76 0.76 0.81 0.77 0.72 0.70 0.76 0.71 0.66 0.63 
 SID Isoleucine, % 1.15 1.06 0.97 0.82 1.05 0.96 0.86 0.77 1.01 0.93 0.84 0.76 0.92 0.83 0.74 0.65 
Analyzed composition                  
 DM2, % - - - - - - - - - - - - 90.81 91.32 91.24 91.38 
 GE2, Mcal/kg - - - - - - - - - - - - 4.25 4.20 4.13 4.08 
 Crude protein, % 29.39 25.10 24.87 22.20 26.60 23.93 22.51 20.61 25.84 24.31 22.51 20.33 24.57 22.01 20.46 18.18 
     Diet Isoflavones                 
   Daidzein3 0.07 0.06 0.06 0.05 0.07 0.07 0.06 0.06 0.06 0.06 0.06 0.07 0.06 0.07 0.06 0.06 
   Glycitein3 0.11 0.10 0.09 0.07 0.10 0.09 0.07 0.07 0.09 0.09 0.08 0.07 0.10 0.09 0.07 0.05 
   Genistein3 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 
   Daidzin4 0.26 0.22 0.27 0.20 0.27 0.26 0.21 0.20 0.25 0.24 0.21 0.19 0.27 0.24 0.21 0.17 
   Glycitin4 0.04 0.07 0.04 0.04 0.09 0.11 0.10 0.13 0.04 0.05 0.04 0.05 0.04 0.05 0.05 0.05 
   Genistin4 0.33 0.27 0.27 0.19 0.30 0.26 0.20 0.16 0.28 0.26 0.22 0.19 0.29 0.24 0.19 0.14 
   6” –O-malonyl-daidzin 0.23 0.19 0.21 0.15 0.19 0.18 0.16 0.14 0.19 0.18 0.15 0.13 0.17 0.15 0.12 0.09 
   6” –O-malonyl-glycitin 0.12 0.17 0.11 0.08 0.10 0.09 0.08 0.07 0.10 0.10 0.08 0.07 0.10 0.09 0.07 0.05 
   6” –O-malonyl-genistin 0.32 0.24 0.26 0.18 0.25 0.24 0.21 0.19 0.24 0.23 0.19 0.17 0.22 0.19 0.15 0.11 
   Total Isoflavones 1.49 1.33 1.32 0.98 1.39 1.31 1.10 1.01 1.25 1.22 1.05 0.95 1.27 1.12 0.94 0.72 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high synthetic AA (HSAA) 
1Values provided by Iowa Select Farms – diet specs 
2Dry matter and gross energy measures were only determined on diets fed during collection periods 
3Isoflavone aglycone form  














Table 2.3. Nutrient composition (as-fed basis) of experimental diets Phase 5-8 
 Phase 5 Phase 6 Phase 7 Phase 8 
Item  HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA 
Formulated composition1                  
 ME, Mcal/kg 3.47 3.46 3.45 3.44 3.49 3.48 3.47 3.45 3.42 3.41 3.40 3.38 3.43 3.42 3.41 3.40 
 Calcium, % 0.48 0.47 0.47 0.46 0.46 0.46 0.46 0.48 0.44 0.44 0.43 0.45 0.42 0.42 0.42 0.40 
 Available phosphorus, %   0.35 0.35 0.34 0.33 0.35 0.34 0.33 0.38 0.26 0.25 0.24 0.29 0.25 0.25 0.24 0.24 
 Total phosphorus, % 0.46 0.44 0.41 0.38 0.43 0.40 0.38 0.41 0.36 0.34 0.31 0.34 0.36 0.33 0.31 0.29 
 Crude protein, % 20.58 18.64 16.52 14.65 18.05 16.09 14.14 12.44 18.93 16.97 15.06 13.17 18.35 16.58 14.80 13.10 
 SID Lysine, % 0.95 0.95 0.95 0.95 0.79 0.78 0.78 0.79 0.74 0.74 0.74 0.73 0.70 0.70 0.70 0.69 
 SID Threonine, % 0.71 0.64 0.60 0.60 0.62 0.55 0.49 0.49 0.61 0.53 0.49 0.49 0.59 0.52 0.46 0.46 
 SID Tryptophan, % 0.22 0.19 0.15 0.15 0.18 0.15 0.12 0.13 0.17 0.15 0.13 0.13 0.17 0.14 0.11 0.11 
 SID TSAA, % 0.70 0.65 0.60 0.55 0.64 0.59 0.54 0.50 0.62 0.57 0.52 0.47 0.61 0.56 0.52 0.47 
 SID Isoleucine, % 0.81 0.72 0.62 0.53 0.70 0.61 0.52 0.44 0.68 0.59 0.50 0.40 0.56 0.57 0.49 0.41 
Analyzed composition                  
 DM2, % - - - - - - - - 90.62 90.79 90.89 90.86 - - - - 
 GE2, Mcal/kg - - - - - - - - 4.22 4.17 4.15 4.06 - - - - 
 Crude protein, % 21.37 18.80 16.40 14.85 19.15 16.63 15.20 13.76 18.81 16.87 14.47 12.50 18.27 16.58 15.38 13.08 
     Diet Isoflavones                 
   Daidzein3 0.06 0.06 0.06 0.06 0.06 0.05 0.05 0.05 0.05 0.06 0.05 0.05 0.04 0.06 0.05 0.06 
   Glycitein3 0.08 0.07 0.06 0.04 0.07 0.05 0.04 0.03 0.05 0.04 0.02 0.01 0.03 0.04 0.03 0.02 
   Genistein3 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 
   Daidzin4 0.20 0.16 0.13 0.09 0.14 0.10 0.05 0.03 0.07 0.07 0.03 0.03 0.07 0.05 0.03 0.02 
   Glycitin4 0.05 0.05 0.05 0.06 0.06 0.06 0.06 0.06 0.05 0.06 0.06 0.06 0.05 0.07 0.07 0.06 
   Genistin4 0.23 0.18 0.13 0.08 0.16 0.11 0.07 0.04 0.09 0.07 0.03 0.01 0.08 0.07 0.05 0.01 
   6” –O-malonyl-daidzin 0.14 0.11 0.08 0.06 0.10 0.07 0.05 0.04 0.10 0.07 0.03 0.00 0.08 0.07 0.04 0.01 
   6” –O-malonyl-glycitin 0.08 0.06 0.05 0.03 0.06 0.05 0.03 0.03 0.05 0.04 0.02 0.01 0.04 0.04 0.02 0.01 
   6” –O-malonyl-genistin 0.17 0.14 0.10 0.07 0.14 0.10 0.08 0.06 0.13 0.10 0.05 0.02 0.10 0.09 0.07 0.04 
   Total Isoflavones 1.02 0.85 0.67 0.49 0.79 0.61 0.43 0.35 0.06 0.52 0.30 0.18 0.50 0.49 0.37 0.24 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high synthetic AA (HSAA) 
1Values provided by Iowa Select Farms – diet specs 
2Dry matter and gross energy measures were only determined on diets fed during collection period 
3Isoflavone aglycone form  












 Table 2.4. Soybean meal (SBM) inclusion level and sex effects on growth performance and carcass composition with a low challenge 
health (LCh) in grow-finish pigs raised under commercial conditions1  
Item 
Treatment3   Sex4 Pooled 
SEM 
P-value2 
HSBM MSBM MSAA HSAA Barrows Mixed Gilts Treatment Sex Treatment´Sex 
No. pens 9 9 9 9 16 4 16     
No. pigs 230 226 228 227 408 101 402     
No. mortality 9 7 12 9 22 2 13     
No. full value 206 201 197 196 355 94 351     
Growth Performance            
 Initial BW, kg 13.3 13.2 13.1 13.4 12.7y 14.1z 13.0y 0.4 0.828 0.003 0.995 
 Final BW, kg 130.9 131.7 128.5 125.9 132.2z 131.8z 123.9y 2.3 0.052 < 0.001 0.805 
 ADG5, kg 0.88a 0.88a 0.84b 0.84b 0.88z 0.88z 0.83y 0.02 0.030 < 0.001 0.807 
 ADFI5, kg 2.05 2.08 2.02 2.05 2.14z 2.08z 1.93y 0.04 0.627 < 0.001 0.865 
 G:F 0.43a 0.42ab 0.42bc 0.41c 0.41x 0.42y 0.43z 0.004 < 0.001 < 0.001 0.560 
 BW CV, % d 0 19.9 21.2 22.5 20.6 21.6 19.3 22.2 2.1 0.637 0.360 0.970 
 BW CV, % d 117 11.3 11.7 12.8 13.0 12.6 11.8 12.3 1.1 0.341 0.754 0.040 
Carcass Performance             
 Market BW, kg 131.2a 132.1a 128.1ab 126.5b 132.4z 131.7z 124.3y 2.1 0.030 < 0.001 0.576 
 HCW, kg 95.0ab 95.4a 92.6b 91.6c 96.1z 94.6z 90.3y 1.4 0.022 < 0.001 0.412 
 Yield, % 72.4 72.3 72.3 72.4 72.6z 71.8y 72.6z 0.3 0.875 0.020 0.977 
 Estimated lean, % 55.1 55.0 55.4 54.7 53.6x 55.2y 56.4z 0.3 0.196 < 0.001 0.338 
 Loin depth, mm 61.1 60.3 60.3 59.0 59.6 61.0 59.9 1.1 0.299 0.391 0.921 
 Fat depth, mm 18.2 18.2 17.5 18.4 20.4z 18.0y 15.9x 0.5 0.311 < 0.001 0.281 
a-c or z-x within a row, least square means lacking a common superscript differ, P < 0.05 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high synthetic AA (HSAA) 
11,000-pigs wean-finish facility populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 terminal sire], this study did not start until 
approximately 34 d post weaning (13.1 ± 0.2 kg of BW), pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2Probability values for main effects of dietary treatment or sex 
3LS means of SBM treatment  
4LS means of sex 









 Table 2.5. Soybean meal (SBM) inclusion level and sex effects on apparent total tract digestibility (ATTD) of DM and GE with a low 
challenge health (LCh) in grow-finish pigs raised under commercial conditions1  
Item  
Treatment3 Sex4 Pooled 
SEM 
P-value2 
HSBM MSBM MSAA HSAA Barrows Gilts Treatment Sex Treatment´Sex 
ATTD, %           
 DM           
  45 kg BW  79.34 79.97 79.65 79.66 79.67 79.64 1.01 0.960 0.968 0.470 
  100 kg BW 82.64 82.96 83.06 81.72 82.30 82.88 0.95 0.629 0.464 0.197 
 GE           
  45 kg BW 77.67 78.15 77.94 78.06 77.91 78.01 1.00 0.976 0.906 0.346 
  100 kg BW 80.81 81.25 81.31 79.78 80.50 81.07 1.11 0.624 0.538 0.251 
a-c or z-x within a row, least square means lacking a common superscript differ, P < 0.05 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high synthetic AA (HSAA) 
11,000-pigs wean-finish facility populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 terminal sire], this study did not start until 
approximately 34 d post weaning (13.1 ± 0.2 kg of BW), pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2Probability values for main effects of dietary treatment or sex 
3LS means of SBM treatment  





















 Table 2.6. Soybean meal (SBM) inclusion level and sex effects on sera isoflavone concentration with a low challenge health (LCh) in 
grow-finish pigs raised under commercial conditions1 
Item 
Time3 Treatment4 Sex5 Pooled 
SEM 
P-value2 
7 d 35 d 63 d 91 d HSBM MSBM MSAA HSAA Barrows Gilts Time Treatment Sex 
Glycitein4, µg/mL 0.10b 0.05c 0.14a 0.04c 0.08 0.08 0.11 0.07 0.09 0.08 0.02 < 0.001 0.120 0.281 
Genistein4, µg/mL 0.35a 0.26b 0.23b 0.15c 0.27 0.26 0.25 0.20 0.27 0.23 0.04 < 0.001 0.101 0.071 
Daidzein4, µg/mL 0.64a 0.42b 0.42b 0.25c 0.46 0.44 0.46 0.36 0.46 0.40 0.06 < 0.001 0.092 0.088 
Total4, µg/mL 1.10a 0.72b 0.78b 0.44c 0.81 0.78 0.82 0.63 0.81 0.71 0.12 < 0.001 0.098 0.082 
a-c or z-x within a row, least square means lacking a common superscript differ, P < 0.05 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high synthetic AA (HSAA) 
11,000-pigs wean-finish facility populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 terminal sire], this study did not start until 
approximately 34 d post weaning (13.1 ± 0.2 kg of BW), pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2Probability values for main effects of dietary time, treatment or sex 
3LS means of time  
4LS means of SBM treatment  























 Table 2.7. Soybean meal (SBM) inclusion level and sex effects on growth performance and carcass composition with a moderate 
challenge health (MCh) in grow-finish pigs raised under commercial conditions1 
Item 
Treatment3 Sex4 Pooled 
SEM 
P-value2 
HSBM MSBM MSAA HSAA Barrows Mixed Gilts Treatment Sex Treatment´Sex 
No. pens 6 9 7 8 12 4 14     
No. pigs 150 225 178 203 296 104 356     
No. mortality 10 17 12 19 24 7 27     
No. full value 119 190 149 168 246 84 296     
Growth 
Performance 
           
 Initial BW, kg 13.5 13.4 14.0 13.7 13.7zy 13.1y 14.2z 0.4 0.407 0.003 0.610 
 Final BW, kg 130.7b 134.2a 131.6ab 128.3b 132.9a 131.3ab 129.4b 1.7 0.014 0.020 0.080 
 ADG5, kg 0.79 0.82 0.79 0.77 0.81 0.79 0.78 0.02 0.109 0.128 0.141 
 ADFI5, kg 1.97 2.02 2.02 2.02 2.12z 1.98zy 1.92y 0.06 0.708 < 0.001 0.473 
 G:F 0.40 0.40 0.39 0.38 0.38y 0.40zy 0.41z 0.01 0.055 < 0.001 0.139 
Carcass 
Performance  
           
 Market BW, 
kg 133.0
a 135.5a 133.2a 129.9b 134.7z 133.1zy 130.9y 1.5 0.008 0.004 0.132 
 HCW, kg 98.0 100.6 98.6 96.7 99.5z 98.9zy 97.0y 1.5 0.058 0.041 0.447 
 Yield, % 73.7 74.3 74.0 74.5 73.9 74.3 74.1 0.4 0.185 0.470 0.674 
 Lean, % 55.0 54.8 55.0 54.6 53.5y 55.0z 56.1z 0.4 0.616  < 0.001 0.894 
 Loin Depth, 
mm 60.0 61.3 61.4 60.2 60.2 61.0 60.9 
1.2 0.564 0.599 0.164 
 Fat Depth, mm 18.2 18.8 18.4 18.9 20.7z 18.4y 16.6x 0.6 0.609 < 0.001 0.927 
a-c or z-x within a row, least square means lacking a common superscript differ, P < 0.05 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high synthetic AA (HSAA) 
11,000-pigs wean-finish facility populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 terminal sire], this study did not start until 
approximately 34 d post weaning (13.1 ± 0.2 kg of BW), pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2Probability values for main effects of dietary treatment or sex 
3LS means of SBM treatment  
4LS means of sex 








 Table 2.8. Soybean meal (SBM) inclusion level and sex effects on sera isoflavone concentration with a moderate challenge health 
(MCh) in grow-finish pigs raised under commercial conditions1 
Item 
Time3 Treatment4 Sex5 Pooled 
SEM 
P-value2 
7 d 35 d 63 d 91 d HSBM MSBM MSAA HSAA Barrows Gilts Time Treatment Sex 
Glycitein, µg/mL 0.05b 0.03b 0.02b 0.10a 0.06z 0.07z 0.04zy 0.02y 0.05 0.04 0.02 < 0.001 < 0.001 0.531 
Genistein, µg/mL 0.25a 0.21a 0.11b 0.20a 0.22z 0.24z 0.18zy 0.14y 0.20 0.18 0.05 0.001 0.011 0.329 
Daidzein, µg/mL 0.43a 0.31b 0.19c 0.36ab 0.38z 0.39z 0.29zy 0.22y 0.33 0.31 0.08 < 0.001 0.007 0.714 
Total, µg/mL 0.73a 0.54b 0.32c 0.66ab 0.67z 0.69z 0.51zy 0.38y 0.58 0.54 0.14 0.001 0.006 0.517 
a-c or z-x within a row, least square means lacking a common superscript differ, P < 0.05 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high synthetic AA (HSAA) 
11,000-pigs wean-finish facility populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 terminal sire], this study did not start until 
approximately 34 d post weaning (13.1 ± 0.2 kg of BW), pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2Probability values for main effects of dietary treatment or sex 
3LS means of time  
4LS means of SBM treatment  




















 Table 2.9. Soybean meal (SBM) inclusion level and sex effects on growth performance and carcass composition with a high challenge 
health (HCh) in grow-finish pigs raised under commercial conditions1 
Item 
Treatment3 Sex4 Pooled 
SEM 
P-value2 
HSBM MSBM MSAA HSAA Barrows Mixed Gilts Treatment Sex Treatment´Sex 
No. pens 9 9 9 9 16 4 16     
No. pigs 222 217 224 222 391 99 395     
No. mortality 51 47 37 53 87 18 83     
No. full value 145 140 162 144 256 69 266     
Growth Performance            
 Initial BW, kg 12.6 12.4 12.5 12.1 12.5 12.2 12.4 0.4 0.583 0.571 0.972 
 Final BW, kg 129.1ab 133.3a 131.2a 125.7b 135.3z 128.7y 125.5y 2.7 0.040 < 0.001 0.167 
 ADG5, kg 0.73 0.73 0.75 0.71 0.76z 0.73zy 0.71y 0.03 0.409 0.009 0.381 
 ADFI5, kg 1.77 1.78 1.87 1.84 1.93z 1.80zy 1.71y 0.07 0.362 < 0.001 0.573 
 G:F 0.41a 0.41ab 0.40b 0.39c 0.39x 0.40y 0.41z 0.004 < 0.001 < 0.001 0.250 
 BW CV, % d 0 26.6 27.2 25.5 25.7 25.9 27.9 24.9 2.1 0.811 0.301 0.974 
 BW CV, % d 
132 
16.0 16.3 14.4 15.3 16.0 16.2 14.4 1.7 0.622 0.234 0.395 
Carcass Performance             
 Market BW, kg 131.8ab 136.1a 133.0ab 127.6b 137.61z 131.3y 127.4y 2.7 0.022 < 0.001 0.377 
 HCW, kg 96.3bc 100.5a 98.0ab 94.1c 101.08z 96.6y 94.0y 1.9 0.015 < 0.001 0.231 
 Yield, % 73.1 73.9 73.7 73.8 73.46 73.6 73.8 0.4 0.118 0.288 0.222 
 Lean, % 55.5 54.4 54.5 55.0 53.28x 54.6y 56.7z 0.6 0.184 < 0.001 0.361 
 Loin Depth, 
mm 61.8 60.0 60.8 59.6 60.66 59.3 61.7 
1.3 0.322 0.143 0.803 
 Fat Depth, mm 17.7 19.2 19.0 18.1 21.08z 18.7y 15.7x 0.9 0.208 < 0.001 0.248 
a-c or z-x within a row, least square means lacking a common superscript differ, P < 0.05 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high synthetic AA (HSAA) 
11,000-pigs wean-finish facility populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 terminal sire], this study did not start until 
approximately 34 d post weaning (13.1 ± 0.2 kg of BW), pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2Probability values for main effects of dietary treatment or sex 
3LS means of SBM treatment  
4LS means of sex 








Table 2.10. Soybean meal (SBM) inclusion level and sex effects on apparent total tract digestibility (ATTD) of DM and GE with a 
high challenge health (HCh) in grow-finish pigs raised under commercial conditions1 
Item  
Treatment3 Sex4 Pooled 
SEM 
P-value2 
HSBM MSBM MSAA HSAA Barrows Gilts Treatment Sex Treatment´Sex 
ATTD, %           
 DM           
  45 kg 81.50 82.68 82.66 83.73 83.14 82.14 1.05 0.339 0.258 0.902 
  100 kg 86.27 86.52 85.62 87.62 86.45 86.57 1.59 0.755 0.925 0.972 
 GE           
  45 kg 80.00 81.16 81.23 82.33 81.77 80.59 1.14 0.376 0.219 0.874 
  100 kg 84.87 85.21 83.94 86.23 84.93 85.19 1.66 0.705 0.847 0.955 
a-c or z-x within a row, least square means lacking a common superscript differ, P < 0.05 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high synthetic AA (HSAA) 
11,000-pigs wean-finish facility populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 terminal sire], this study did not start until 
approximately 34 d post weaning (13.1 ± 0.2 kg of BW), pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2Probability values for main effects of dietary treatment or sex 
3LS means of SBM treatment  





















 Table 2.11. Soybean meal (SBM) inclusion level and sex effects on sera isoflavone concentration with a high challenge health (HCh) 
in grow-finish pigs raised under commercial conditions1 
Item 
Time3 Treatment4 Sex5 Pooled 
SEM 
P-value2 
7 d 35 d 63 d 91 d HSBM MSBM MSAA HSAA Barrows Gilts Time Treatment Sex 
Glycitein, µg/mL 0.05 0.10 0.05 0.03 0.06 0.04 0.06 0.08 0.10 0.12 0.02 < 0.001 0.334 0.627 
Genistein, µg/mL 0.22 0.18 0.20 0.25 0.24 0.21 0.20 0.20 0.23 0.20 0.05 0.088 0.614 0.321 
Daidzein, µg/mL 0.43 0.35 0.31 0.35 0.39 0.36 0.34 0.36 0.38 0.34 0.08 0.066 0.858 0.400 
Total, µg/mL 0.71 0.64 0.56 0.64 0.69 0.61 0.59 0.63 0.67 0.60 0.15 0.341 0.807 0.394 
a-c or z-x within a row, least square means lacking a common superscript differ, P < 0.05 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high synthetic AA (HSAA) 
11,000-pigs wean-finish facility populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 terminal sire], this study did not start until 
approximately 34 d post weaning (13.1 ± 0.2 kg of BW), pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2Probability values for main effects of dietary treatment or sex 
3LS means of time  
4LS means of SBM treatment  






















 Table 2.12. Oral fluid porcine reproductive and respiratory syndrome virus (PRRSV) concentration by PCR of three experiments, low 
challenge health (LCh), moderate challenge health (MCh) and high challenge health (HCh), on d 7, 63 and 105 in grow-finish pigs 
raised under commercial conditions1 
Item LCh MCh HCh 
d 72  4.76 5.49 6.20 
d 632 4.08 3.72 4.65 
d 1052 0.00 3.46 1.18 
1Three1,000-pigs wean-finish facilities populated with 936 crossbred pigs each [Cambrough female (PIC 1050) x DNA600 terminal sire], these studies did not 
start until approximately 34 d post weaning (13.1 ± 0.2 kg of BW), pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 






























 Table 2.13. NRC total amino acid composition (as-fed basis) of the experimental diets Phase 1-4 
 Phase 14 Phase 25 Phase 36 Phase 47 
Amino Acids HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA 
Total Lysine                 
Formulated1 1.613 1.603 1.595 1.573 1.455 1.449 1.427 1.419 1.393 1.379 1.371 1.363 1.247 1.236 1.226 1.215 
Assayed2 1.653 1.613 1.570 1.507 1.440 1.393 1.390 1.433 1.340 1.327 1.343 1.180 1.323 1.313 1.220 1.190 
Requirement3 1.400 1.400 1.400 1.400 1.400 1.400 1.400 1.400 1.120 1.120 1.120 1.120 0.970 0.970 0.970 0.970 
Total Threonine                  
Formulated1 1.131 1.047 1.005 0.982 1.040 0.956 0.897 0.887 1.005 0.929 0.870 0.859 0.920 0.834 0.786 0.771 
Assayed2 1.120 1.003 0.973 0.893 1.007 0.903 0.883 0.843 0.990 0.900 0.863 0.747 0.933 0.843 0.753 0.743 
Requirement3 0.870 0.870 0.870 0.870 0.870 0.870 0.870 0.870 0.720 0.720 0.720 0.720 0.640 0.640 0.640 0.640 
Total Methionine                 
Formulated1 0.467 0.442 0.465 0.492 0.439 0.414 0.409 0.428 0.430 0.407 0.384 0.378 0.404 0.378 0.353 0.337 
Assayed2 0.420 0.373 0.363 0.313 0.387 0.357 0.337 0.310 0.410 0.350 0.340 0.287 0.377 0.353 0.300 0.293 
Requirement3 0.400 0.400 0.400 0.400 0.400 0.400 0.400 0.400 0.320 0.320 0.320 0.320 0.280 0.280 0.280 0.280 
Total Tryptophan                 
Formulated1 0.361 0.329 0.297 0.258 0.362 0.294 0.258 0.230 0.312 0.283 0.253 0.223 0.280 0.247 0.214 0.196 
Assayed2 0.350 0.297 0.290 0.270 0.320 0.293 0.260 0.237 0.330 0.307 0.280 0.237 0.297 0.273 0.223 0.207 
Requirement3 0.230 0.230 0.230 0.230 0.230 0.230 0.230 0.230 0.190 0.190 0.190 0.190 0.170 0.170 0.170 0.170 
Total TSAA                 
Formulated1 0.929 0.877 0.874 0.856 0.873 0.821 0.786 0.777 0.853 0.805 0.757 0.727 0.779 0.746 0.693 0.650 
Assayed2 0.833 0.740 0.727 0.620 0.767 0.710 0.680 0.617 0.783 0.703 0.683 0.583 0.750 0.710 0.607 0.583 
Requirement3 0.790 0.790 0.790 0.790 0.790 0.790 0.790 0.790 0.650 0.650 0.650 0.650 0.570 0.570 0.570 0.570 
Total Isoleucine                  
Formulated1 1.275 1.175 1.079 0.913 1.167 1.067 0.957 0.856 1.125 1.035 0.943 0.851 1.025 0.924 0.823 0.722 
Assayed2 1.340 1.130 1.087 0.873 1.177 1.047 0.973 0.850 1.123 1.003 0.927 0.753 1.093 0.980 0.820 0.733 
Requirement3 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.590 0.590 0.590 0.590 0.520 0.520 0.520 0.520 
Bold, signifies if the assayed value is below requirement  
1Calculated total value of diet, based on diet formulation (NRC, 2012) 
2Assayed total amino acid  
3Total amino acid requirement (NRC, 2012)  
415-21 kg pigs 
521-27 kg pigs 
627-46 kg pigs 
746-63 kg pigs 











 Table 2.14. NRC total amino acid composition (as-fed basis) of the experimental diets Phase 5-8 
 Phase 54 Phase 65 Phase 76 Phase 87 
Amino Acids HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA 
Total Lysine                 
Formulated1 1.069 1.063 1.041 1.034 1.069 1.063 1.041 1.034 1.069 1.063 1.041 1.034 1.069 1.063 1.041 1.034 
Assayed2 1.073 1.400 0.957 0.967 1.073 1.400 0.957 0.967 1.073 1.400 0.957 0.967 1.073 1.400 0.957 0.967 
Requirement3 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 
Total Threonine                  
Formulated1 0.816 0.730 0.676 0.666 0.816 0.730 0.676 0.666 0.816 0.730 0.676 0.666 0.816 0.730 0.676 0.666 
Assayed2 0.800 0.697 0.633 0.600 0.800 0.697 0.633 0.600 0.800 0.697 0.633 0.600 0.800 0.697 0.633 0.600 
Requirement3 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 
Total Methionine                 
Formulated1 0.372 0.346 0.318 0.293 0.372 0.346 0.318 0.293 0.372 0.346 0.318 0.293 0.372 0.346 0.318 0.293 
Assayed2 0.363 0.327 0.270 0.230 0.363 0.327 0.270 0.230 0.363 0.327 0.270 0.230 0.363 0.327 0.270 0.230 
Requirement3 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 
Total Tryptophan                 
Formulated1 0.240 0.208 0.172 0.164 0.240 0.208 0.172 0.164 0.240 0.208 0.172 0.164 0.240 0.208 0.172 0.164 
Assayed2 0.250 0.203 0.183 0.173 0.250 0.203 0.183 0.173 0.250 0.203 0.183 0.173 0.250 0.203 0.183 0.173 
Requirement3 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 
Total TSAA                 
Formulated1 0.733 0.680 0.623 0.569 0.733 0.680 0.623 0.569 0.733 0.680 0.623 0.569 0.733 0.680 0.623 0.569 
Assayed2 0.690 0.637 0.543 0.470 0.690 0.637 0.543 0.470 0.690 0.637 0.543 0.470 0.690 0.637 0.543 0.470 
Requirement3 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 
Total Isoleucine                  
Formulated1 0.903 0.802 0.691 0.590 0.903 0.802 0.691 0.590 0.903 0.802 0.691 0.590 0.903 0.802 0.691 0.590 
Assayed2 0.907 0.780 0.667 0.567 0.907 0.780 0.667 0.567 0.907 0.780 0.667 0.567 0.907 0.780 0.667 0.567 
Requirement3 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 
Bold, signifies if the assayed value is below requirement 
1Calculated total value of diet, based on diet formulation (NRC, 2012) 
2Assayed total amino acid  
3Total amino acid requirement (NRC 2012)  
415-21 kg pigs 
521-27 kg pigs 
627-46 kg pigs 
746-63 kg pigs 











 Table 2.15. NRC SID amino acid composition (as-fed basis) of the experimental diets Phase 1-4 
 Phase 14 Phase 25 Phase 36 Phase 47 
Amino Acids HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA 
SID Lysine                 
Formulated1 1.375 1.379 1.384 1.386 1.375 1.379 1.384 1.386 1.375 1.379 1.384 1.386 1.375 1.379 1.384 1.386 
Assayed2 1.300 1.255 1.209 1.139 1.300 1.255 1.209 1.139 1.300 1.255 1.209 1.139 1.300 1.255 1.209 1.139 
Requirement3 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 
SID Threonine                  
Formulated1 0.928 0.855 0.823 0.820 0.928 0.855 0.823 0.820 0.928 0.855 0.823 0.820 0.928 0.855 0.823 0.820 
Assayed2 0.892 0.795 0.767 0.697 0.892 0.795 0.767 0.697 0.892 0.795 0.767 0.697 0.892 0.795 0.767 0.697 
Requirement3 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 
SID Methionine                 
Formulated1 0.405 0.382 0.407 0.437 0.405 0.382 0.407 0.437 0.405 0.382 0.407 0.437 0.405 0.382 0.407 0.437 
Assayed2 0.360 0.319 0.309 0.265 0.360 0.319 0.309 0.265 0.360 0.319 0.309 0.265 0.360 0.319 0.309 0.265 
Requirement3 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 
SID Tryptophan                 
Formulated1 0.318 0.289 0.260 0.225 0.318 0.289 0.260 0.225 0.318 0.289 0.260 0.225 0.318 0.289 0.260 0.225 
Assayed2 0.292 0.246 0.239 0.219 0.292 0.246 0.239 0.219 0.292 0.246 0.239 0.219 0.292 0.246 0.239 0.219 
Requirement3 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 
SID TSAA                 
Formulated1 0.711 0.680 0.696 0.713 0.711 0.680 0.696 0.713 0.711 0.680 0.696 0.713 0.711 0.680 0.696 0.713 
Assayed2 0.693 0.613 0.600 0.509 0.693 0.613 0.600 0.509 0.693 0.613 0.600 0.509 0.693 0.613 0.600 0.509 
Requirement3 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 
SID Isoleucine                  
Formulated1 1.102 1.012 0.925 0.776 1.102 1.012 0.925 0.776 1.102 1.012 0.925 0.776 1.102 1.012 0.925 0.776 
Assayed2 1.128 0.947 0.906 0.722 1.128 0.947 0.906 0.722 1.128 0.947 0.906 0.722 1.128 0.947 0.906 0.722 
Requirement3 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 
Bold, signifies if the assayed value is below requirement 
1Calculated SID value of diet, based on diet formulation (NRC 2012) 
2Assayed total amino acid × diet digestibility (NRC 2012)  
3Amino acid requirement (NRC, 2012)  
415-21 kg pigs 
521-27 kg pigs 
627-46 kg pigs 
746-63 kg pigs 











 Table 2.16. NRC SID amino acid composition (as-fed basis) of the experimental diets Phase 5-8 
 Phase 54 Phase 65 Phase 76 Phase 87 
Amino Acids HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA 
SID Lysine                 
Formulated1 0.883 0.891 0.885 0.892 0.883 0.891 0.885 0.892 0.883 0.891 0.885 0.892 0.883 0.891 0.885 0.892 
Assayed2 0.809 0.775 0.705 0.704 0.809 0.775 0.705 0.704 0.809 0.775 0.705 0.704 0.809 0.775 0.705 0.704 
Requirement3 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 
SID Threonine                  
Formulated1 0.655 0.581 0.539 0.541 0.655 0.581 0.539 0.541 0.655 0.581 0.539 0.541 0.655 0.581 0.539 0.541 
Assayed2 0.623 0.540 0.487 0.459 0.623 0.540 0.487 0.459 0.623 0.540 0.487 0.459 0.623 0.540 0.487 0.459 
Requirement3 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 
SID Methionine                 
Formulated1 0.318 0.294 0.269 0.245 0.318 0.294 0.269 0.245 0.318 0.294 0.269 0.245 0.318 0.294 0.269 0.245 
Assayed2 0.307 0.275 0.226 0.192 0.307 0.275 0.226 0.192 0.307 0.275 0.226 0.192 0.307 0.275 0.226 0.192 
Requirement3 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 
SID Tryptophan                 
Formulated1 0.208 0.177 0.144 0.139 0.208 0.177 0.144 0.139 0.208 0.177 0.144 0.139 0.208 0.177 0.144 0.139 
Assayed2 0.203 0.164 0.146 0.137 0.203 0.164 0.146 0.137 0.203 0.164 0.146 0.137 0.203 0.164 0.146 0.137 
Requirement3 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 
SID TSAA                 
Formulated1 0.592 0.560 0.525 0.492 0.592 0.560 0.525 0.492 0.592 0.560 0.525 0.492 0.592 0.560 0.525 0.492 
Assayed2 0.567 0.521 0.442 0.381 0.567 0.521 0.442 0.381 0.567 0.521 0.442 0.381 0.567 0.521 0.442 0.381 
Requirement3 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 
SID Isoleucine                  
Formulated1 0.766 0.675 0.576 0.485 0.766 0.675 0.576 0.485 0.766 0.675 0.576 0.485 0.766 0.675 0.576 0.485 
Assayed2 0.749 0.642 0.545 0.461 0.749 0.642 0.545 0.461 0.749 0.642 0.545 0.461 0.749 0.642 0.545 0.461 
Requirement3 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 
Bold, signifies if the assayed value is below requirement 
1Calculated SID value of diet, based on diet formulation (NRC, 2012) 
2Assayed total amino acid × diet digestibility (NRC, 2012)  
3Amino acid requirement (NRC, 2012)  
463-78 kg pigs 
578-90 kg pigs 
690-109 kg pigs 
7110-130 kg pigs 











 Table 2.17. Eva Pig total amino acid composition (as-fed basis) of the experimental diets Phase 1-4 
 Phase 14 Phase 25 Phase 36 Phase 47 
Amino Acids HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA 
Total Lysine                 
Formulated1 1.430 1.437 1.447 1.455 1.430 1.437 1.447 1.455 1.430 1.437 1.447 1.455 1.430 1.437 1.447 1.455 
Assayed2 1.653 1.613 1.570 1.507 1.653 1.613 1.570 1.507 1.653 1.613 1.570 1.507 1.653 1.613 1.570 1.507 
Requirement3 1.400 1.400 1.400 1.400 1.400 1.400 1.400 1.400 1.400 1.400 1.400 1.400 1.400 1.400 1.400 1.400 
Total Threonine                  
Formulated1 1.042 0.969 0.936 0.932 1.042 0.969 0.936 0.932 1.042 0.969 0.936 0.932 1.042 0.969 0.936 0.932 
Assayed2 1.120 1.003 0.973 0.893 1.120 1.003 0.973 0.893 1.120 1.003 0.973 0.893 1.120 1.003 0.973 0.893 
Requirement3 0.870 0.870 0.870 0.870 0.870 0.870 0.870 0.870 0.870 0.870 0.870 0.870 0.870 0.870 0.870 0.870 
Total Methionine                 
Formulated1 0.434 0.411 0.444 0.488 0.434 0.411 0.444 0.488 0.434 0.411 0.444 0.488 0.434 0.411 0.444 0.488 
Assayed2 0.420 0.373 0.363 0.313 0.420 0.373 0.363 0.313 0.420 0.373 0.363 0.313 0.420 0.373 0.363 0.313 
Requirement3 0.400 0.400 0.400 0.400 0.400 0.400 0.400 0.400 0.400 0.400 0.400 0.400 0.400 0.400 0.400 0.400 
Total Tryptophan                 
Formulated1 0.310 0.283 0.256 0.225 0.310 0.283 0.256 0.225 0.310 0.283 0.256 0.225 0.310 0.283 0.256 0.225 
Assayed2 0.350 0.297 0.290 0.270 0.350 0.297 0.290 0.270 0.350 0.297 0.290 0.270 0.350 0.297 0.290 0.270 
Requirement3 0.230 0.230 0.230 0.230 0.230 0.230 0.230 0.230 0.230 0.230 0.230 0.230 0.230 0.230 0.230 0.230 
Total TSAA                 
Formulated1 0.885 0.839 0.850 0.854 0.885 0.839 0.850 0.854 0.885 0.839 0.850 0.854 0.885 0.839 0.850 0.854 
Assayed2 0.833 0.740 0.727 0.620 0.833 0.740 0.727 0.620 0.833 0.740 0.727 0.620 0.833 0.740 0.727 0.620 
Requirement3 0.790 0.790 0.790 0.790 0.790 0.790 0.790 0.790 0.790 0.790 0.790 0.790 0.790 0.790 0.790 0.790 
Total Isoleucine                  
Formulated1 1.185 1.095 1.007 0.857 1.185 1.095 1.007 0.857 1.185 1.095 1.007 0.857 1.185 1.095 1.007 0.857 
Assayed2 1.340 1.130 1.087 0.873 1.340 1.130 1.087 0.873 1.340 1.130 1.087 0.873 1.340 1.130 1.087 0.873 
Requirement3 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 
Bold, signifies if the assayed value is below requirement 
1Expected total value of diet, based on diet formulation (Eva pig, Ajinomoto, Itasca, IL) 
2Assayed total amino acid  
3Total amino acid requirement (NRC 2012)  
415-21 kg pigs 
521-27 kg pigs 
627-46 kg pigs 
746-63 kg pigs 











 Table 2.18. Eva Pig total amino acid composition (as-fed basis) of the experimental diets Phase 5-8 
 Phase 54 Phase 65 Phase 76 Phase 87 
Amino Acids HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA 
Total Lysine                 
Formulated1 0.946 0.958 0.956 0.967 0.946 0.958 0.956 0.967 0.946 0.958 0.956 0.967 0.946 0.958 0.956 0.967 
Assayed2 1.073 1.040 0.957 0.967 1.073 1.040 0.957 0.967 1.073 1.040 0.957 0.967 1.073 1.040 0.957 0.967 
Requirement3 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 0.970 
Total Threonine                  
Formulated1 0.765 0.690 0.648 0.650 0.765 0.690 0.648 0.650 0.765 0.690 0.648 0.650 0.765 0.690 0.648 0.650 
Assayed2 0.800 0.697 0.633 0.600 0.800 0.697 0.633 0.600 0.800 0.697 0.633 0.600 0.800 0.697 0.633 0.600 
Requirement3 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 0.640 
Total Methionine                 
Formulated1 0.345 0.321 0.295 0.270 0.345 0.321 0.295 0.270 0.345 0.321 0.295 0.270 0.345 0.321 0.295 0.270 
Assayed2 0.363 0.327 0.270 0.230 0.363 0.327 0.270 0.230 0.363 0.327 0.270 0.230 0.363 0.327 0.270 0.230 
Requirement3 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 0.280 
Total Tryptophan                 
Formulated1 0.208 0.180 0.149 0.146 0.208 0.180 0.149 0.146 0.208 0.180 0.149 0.146 0.208 0.180 0.149 0.146 
Assayed2 0.250 0.203 0.183 0.173 0.250 0.203 0.183 0.173 0.250 0.203 0.183 0.173 0.250 0.203 0.183 0.173 
Requirement3 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 0.170 
Total TSAA                 
Formulated1 0.708 0.660 0.607 0.559 0.708 0.660 0.607 0.559 0.708 0.660 0.607 0.559 0.708 0.660 0.607 0.559 
Assayed2 0.690 0.637 0.543 0.470 0.690 0.637 0.543 0.470 0.690 0.637 0.543 0.470 0.690 0.637 0.543 0.470 
Requirement3 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 0.570 
Total Isoleucine                  
Formulated1 0.847 0.756 0.656 0.564 0.847 0.756 0.656 0.564 0.847 0.756 0.656 0.564 0.847 0.756 0.656 0.564 
Assayed2 0.907 0.780 0.667 0.567 0.907 0.780 0.667 0.567 0.907 0.780 0.667 0.567 0.907 0.780 0.667 0.567 
Requirement3 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 
Bold, signifies if the assayed value is below requirement 
1Expected total value of diet, based on diet formulation (Eva pig, Ajinomoto, Itasca, IL) 
2Assayed total amino acid  
3Total amino acid requirement (NRC 2012)  
463-78 kg pigs 
578-90 kg pigs 
690-109 kg pigs 
7110-130 kg pigs 











 Table 2.19. Eva Pig SID amino acid composition (as-fed basis) of the experimental diets Phase 1-4 
 Phase 14 Phase 25 Phase 36 Phase 47 
Amino Acids HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA 
SID Lysine                 
Formulated1 1.240 1.259 1.280 1.307 1.240 1.259 1.280 1.307 1.240 1.259 1.280 1.307 1.240 1.259 1.280 1.307 
Assayed2 1.340 1.299 1.256 1.192 1.340 1.299 1.256 1.192 1.340 1.299 1.256 1.192 1.340 1.299 1.256 1.192 
Requirement3 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 1.230 
SID Threonine                  
Formulated1 0.866 0.802 0.779 0.791 0.866 0.802 0.779 0.791 0.866 0.802 0.779 0.791 0.866 0.802 0.779 0.791 
Assayed2 0.916 0.819 0.793 0.725 0.916 0.819 0.793 0.725 0.916 0.819 0.793 0.725 0.916 0.819 0.793 0.725 
Requirement3 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 0.730 
SID Methionine                 
Formulated1 0.385 0.364 0.389 0.420 0.385 0.364 0.389 0.420 0.385 0.364 0.389 0.420 0.385 0.364 0.389 0.420 
Assayed2 0.374 0.332 0.323 0.279 0.374 0.332 0.323 0.279 0.374 0.332 0.323 0.279 0.374 0.332 0.323 0.279 
Requirement3 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 0.360 
SID Tryptophan                 
Formulated1 0.269 0.244 0.220 0.194 0.269 0.244 0.220 0.194 0.269 0.244 0.220 0.194 0.269 0.244 0.220 0.194 
Assayed2 0.291 0.245 0.238 0.219 0.291 0.245 0.238 0.219 0.291 0.245 0.238 0.219 0.291 0.245 0.238 0.219 
Requirement3 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 0.200 
SID TSAA                 
Formulated1 0.710 0.680 0.696 0.712 0.710 0.680 0.696 0.712 0.710 0.680 0.696 0.712 0.710 0.680 0.696 0.712 
Assayed2 0.722 0.641 0.630 0.539 0.722 0.641 0.630 0.539 0.722 0.641 0.630 0.539 0.722 0.641 0.630 0.539 
Requirement3 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 0.680 
SID Isoleucine                  
Formulated1 1.028 0.948 0.870 0.736 1.028 0.948 0.870 0.736 1.028 0.948 0.870 0.736 1.028 0.948 0.870 0.736 
Assayed2 1.149 0.969 0.931 0.747 1.149 0.969 0.931 0.747 1.149 0.969 0.931 0.747 1.149 0.969 0.931 0.747 
Requirement3 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 0.630 
Bold, signifies if the assayed value is below requirement 
1Expected SID value of diet, based on diet formulation (Eva pig, Ajinomoto, Itasca, IL) 
2Assayed total amino acid × diet digestibility (Eva pig, Ajinomoto, Itasca, IL) 
3Amino acid requirement (NRC 2012)  
415-21 kg pigs 
521-27 kg pigs 
627-46 kg pigs 
746-63 kg pigs 











 Table 2.20. Eva Pig SID amino acid composition (as-fed basis) of the experimental diets Phase 5-8 
 Phase 54 Phase 65 Phase 76 Phase 87 
Amino Acids HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA HSBM MSBM MSAA HSAA 
SID Lysine                 
Formulated1 0.800 0.823 0.834 0.857 0.800 0.823 0.834 0.857 0.800 0.823 0.834 0.857 0.800 0.823 0.834 0.857 
Assayed2 0.847 0.815 0.744 0.747 0.847 0.815 0.744 0.747 0.847 0.815 0.744 0.747 0.847 0.815 0.744 0.747 
Requirement3 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 
SID Threonine                  
Formulated1 0.625 0.560 0.529 0.541 0.625 0.560 0.529 0.541 0.625 0.560 0.529 0.541 0.625 0.560 0.529 0.541 
Assayed2 0.649 0.564 0.512 0.484 0.649 0.564 0.512 0.484 0.649 0.564 0.512 0.484 0.649 0.564 0.512 0.484 
Requirement3 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 0.520 
SID Methionine                 
Formulated1 0.304 0.283 0.259 0.237 0.304 0.283 0.259 0.237 0.304 0.283 0.259 0.237 0.304 0.283 0.259 0.237 
Assayed2 0.324 0.291 0.240 0.205 0.324 0.291 0.240 0.205 0.324 0.291 0.240 0.205 0.324 0.291 0.240 0.205 
Requirement3 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 0.240 
SID Tryptophan                 
Formulated1 0.177 0.152 0.124 0.124 0.177 0.152 0.124 0.124 0.177 0.152 0.124 0.124 0.177 0.152 0.124 0.124 
Assayed2 0.203 0.164 0.147 0.138 0.203 0.164 0.147 0.138 0.203 0.164 0.147 0.138 0.203 0.164 0.147 0.138 
Requirement3 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 0.150 
SID TSAA                 
Formulated1 0.595 0.564 0.530 0.499 0.595 0.564 0.530 0.499 0.595 0.564 0.530 0.499 0.595 0.564 0.530 0.499 
Assayed2 0.601 0.554 0.473 0.410 0.601 0.554 0.473 0.410 0.601 0.554 0.473 0.410 0.601 0.554 0.473 0.410 
Requirement3 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 0.480 
SID Isoleucine                  
Formulated1 0.727 0.646 0.556 0.474 0.727 0.646 0.556 0.474 0.727 0.646 0.556 0.474 0.727 0.646 0.556 0.474 
Assayed2 0.776 0.667 0.570 0.484 0.776 0.667 0.570 0.484 0.776 0.667 0.570 0.484 0.776 0.667 0.570 0.484 
Requirement3 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 0.450 
Bold, signifies if the assayed value is below requirement 
1Expected SID value of diet, based on diet formulation (Eva pig, Ajinomoto, Itasca, IL) 
2Assayed total amino acid × diet digestibility (Eva pig, Ajinomoto, Itasca, IL) 
3Amino acid requirement (NRC 2012)  
463-78 kg pigs 
578-90 kg pigs 
690-109 kg pigs 
7110-130 kg pigs 




Figure 2.1 Soybean meal (SBM) inclusion level and sex effects on sera glycitein 
concentration with a high challenge health (HCh) in grow-finish pigs raised under 
commercial conditions1 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high 
synthetic AA (HSAA) 
11,000-pigs wean-finish facility populated with 936 crossbred pigs [Cambrough female (PIC 1050) x 
DNA600 terminal sire], this study did not start until approximately 34 d post weaning (13.1 ± 0.2 kg of 
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Figure 2.2. Soybean meal (SBM) inclusion level and sex effects on sera genistein 
concentration with a high challenge health (HCh) in grow-finish pigs raised under 
commercial conditions1 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high 
synthetic AA (HSAA) 
11,000-pigs wean-finish facility populated with 936 crossbred pigs [Cambrough female (PIC 1050) x 
DNA600 terminal sire], this study did not start until approximately 34 d post weaning (13.1 ± 0.2 kg of 
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Figure 2.3. Soybean meal (SBM) inclusion level and sex effects on total sera 
concentration with a high challenge health (HCh) in grow-finish pigs raised under 
commercial conditions1 
High soybean meal (SBM) (HSBM), moderate SBM (MSBM), moderate synthetic AA (MSAA), high 
synthetic AA (HSAA) 
11,000-pigs wean-finish facility populated with 936 crossbred pigs [Cambrough female (PIC 1050) x 
DNA600 terminal sire], this study did not start until approximately 34 d post weaning (13.1 ± 0.2 kg of 
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Figure 2.4. Five 1,000 pig research barns utilized in three con-current experiments assessing the 16 
growth and carcass performance of pigs experiencing a naturally occurring health challenge 17 
(HC) when fed SBM at different levels in their diets 18 
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 Understanding how disease affects commercial production is imperative for pig 53 
producers to quantify its full impact on pig performance, carcass quality and net returns. The 54 
objective of this experiment was to assess the productivity and economic importance of naturally 55 
occurring health challenges under commercial conditions. Three 1,000 pig grow-finish facilities 56 
received 936 pigs each. The experimental period started approximately 34 d post placement at an 57 
average start BW of 13.1 ± 0.2 kg. Barns were characterized based on the relative health 58 
challenge (HC), determined by diagnostic assessments as the main characterization tool, along 59 
with other health indicators. Barns were characterized as low challenge health (LCh), moderate 60 
challenge health (MCh) and high challenge health (HCh). All barns tested positive for porcine 61 
reproductive and respiratory syndrome virus (PRRSV) infection prior to the start of the 62 
experiment. Additionally, the MCh and HCh barns experienced influenza type A virus of swine 63 
(IAV-S). Similar to commercial production conditions, the disease challenge was not imposed 64 
but rather occurred naturally. Reduced ADG, ADFI and G:F were observed with an increased 65 
HC (P < 0.001). Similarly, mortality was increased when the HC increased (P < 0.001). 66 
Decreased ADG increased days to achieve market BW, by 10 and 15 d in the MCh and HCh 67 
treatments compared with LCh, respectively (P < 0.001). No differences were observed for 68 
percent lean, loin depth or fat depth (P > 0.10). The economic impact of the HC was assessed by 69 
applying these growth performance data to two economic models encompassing the two main 70 
marketing methods used by U.S. pig producers: fixed-weight and fixed-time. Production losses 71 
attributed to the variation in disease severity that occurred in the present study were between 72 
$9.47 and $23.27 U.S dollars (USD)/pig marketed at fixed-weight or between $12.61 and $25.27 73 
USD/pig marketed at fixed-time, depending on feed costs and market hog prices. In summary, an 74 
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increased disease sweverity that is due, at least partially, to PRRSV and IAV-S will reduce 75 
growth performance and pig outcome of grow-finish pigs. These reductions will result in 76 
economic losses of considerable magnitude.  77 
  78 
Keywords: economics, swine influenza virus (IAV-S), porcine reproductive and respiratory 79 
syndrome virus (PRRSV), swine 80 
 81 
Introduction 82 
In 2016, 63% of the total U.S market hog sales originated in Iowa and the surrounding 6 83 
states (USDA, 2017). While Midwest swine production is in a unique position of being favorably 84 
located geographically, such density increases the risk of disease transmission among production 85 
units. 86 
Porcine reproductive and respiratory syndrome virus (PRRSV) is the costliest disease 87 
facing pig producers. Holtkamp et al. (2013) estimated annual losses of 664 million U.S. dollar 88 
(USD) due to PRRSV. While there are no published data on the costs attributed to influenza type 89 
A virus of swine (IAV-S), it is considered an economically important disease due to reduced 90 
growth rates and increased morbidity. A co-challenge of PRRSV with IAV-S or other pathogens 91 
can be more costly due to the compounding of disease symptoms (Zimmerman et al., 2012). 92 
Most disease research is performed in controlled research facilities with attention directed 93 
at a single pathogen in order to elucidate the infection mechanism and better understand 94 
biological responses (Rochell et al., 2015; Che et al., 2015). Fully understanding the ways 95 
disease impacts commercial production is imperative to quantify the influence of disease on pig 96 
performance and net financial returns. Studies conducted in a research facility have the 97 
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advantage of being well controlled but the disadvantage of uncertain relevance to practical 98 
conditions; conversely, studies carried out on commercial farms enhance relevance but 99 
maintaining proper controls can be difficult. The ideal situation would be an intensive, well- 100 
managed study carried out in a commercial research facility which requires attention to detail, 101 
adherence to accepted standards of scientific endeavor and a great deal of on-site labor. 102 
The objective of this experiment was to assess the relative impact of naturally occurring 103 
health challenges under commercial conditions on productivity and financial returns, 104 
hypothesizing that a more severe health challenge would decrease productivity and reduce net 105 
income. 106 
  107 
Materials and methods 108 
All experimental procedures adhered to guidelines for the ethical and humane use of 109 
animals for research and were approved by the Iowa State University Institutional Animal Care 110 
and Use Committee (number 15-I-0009-A).  111 
 112 
Animals, housing and management 113 
Three 1,000 head grow-finish barns located on the same geographical site in Iowa were 114 
each populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 terminal 115 
sire]; pigs were received from two different sow sources, although both were identical in genetic 116 
origin.  117 
The 3 barns were identical in design, management and operation and pigs received 118 
identical diets during the experiment. Each barn contained 46 pens, (16.8 m2), with completely 119 
slatted concrete floors, metal pen dividers and gates, 2 nipple water drinkers, and one, 5-space 120 
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stainless-steel dry feeder. Feed was delivered by an automatic system that delivered specific 121 
amounts of feed to specific pens (Feedlogic Corporation, Willmar, MN). Each barn was 122 
equipped with identical integrated ventilation controllers (Expert control, VPN 110, Automated 123 
Production Systems, Assumption, IL), which regulated exhaust fans, air inlets and heaters. This 124 
system maintained a stable interior thermal environment based on a temperature curve.  125 
Thirty-six pens were filled with 26 weaned pigs each at the time of allotment. At 126 
placement, pigs were allotted by sex (16 barrow pens, 16 gilt pens and 4 mixed sex pens) and 127 
size. Based on visual assessment, each pen received 6 “small size”, 14 “medium size” and 6 128 
“large size” pigs. This procedure helped to ensure a similar BW distribution among pens within 129 
each barn. Pigs were placed on-site at weaning, but this study did not start until approximately 34 130 
d post weaning (13.1 ± 0.2 kg of BW). Pigs remained on test until achieving marketing BW of 131 
approximately 130.5 ± 1.4 kg. 132 
All barns were placed on the same feeding program consisting of 8 dietary phases, all 133 
manufactured at the same feed mill (Mid State Milling, State Center, IA). Pigs were provided ad 134 
libitum access to feed and water. All pigs were cared for and managed according to the Iowa 135 
Select Farms Select Care program procedures by the same personnel and same veterinary 136 
services throughout the course of this study.  137 
 138 
Experimental design 139 
Each of the 3 barns were characterized according to the overall observed health challenge 140 
(HC). The HC was considered the applied treatment. Oral fluids were collected on d 7, 63 and 141 
105 to monitor pathogen exposure. Mortality, morbidity and medication treatments were 142 
recorded daily to further assist in characterizing the health challenge within each barn. Daily 143 
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animal observations aided in ensuring all animals received appropriate care. Based on this 144 
approach to characterize the HC, barns were characterized relative to each other as low challenge 145 
health (LCh), moderate challenge health (MCh) and high challenge health (HCh). The disease 146 
challenges experienced by the barns were not imposed but rather occurred naturally, similar to 147 
what occurs in commercial production. The goal was to maintain a separate HC in each barn for 148 
the duration of the experiment.  149 
 150 
Biosecurity 151 
A strict biosecurity protocol was established to avoid pathogen transfer among barns, as 152 
barns were in close proximity to one another; barns were separated by only 15.2 m. Personnel 153 
were required to shower upon arrival at the farm. Personnel movement was strictly limited to 154 
LCh followed by MCh followed by HCh. Boot washes with Virocid disinfectant (CID Lines, 155 
Belgium) were used upon entering and exiting each barn. Tyvex suits (Uline, Pleasant Prairie, 156 
WI.) were placed over coveralls and boots changed prior to entrance into each barn. No re-entry 157 
into any barn was permitted within the same day unless the individual re-showered and put on 158 
clean coveralls. All tools remained in each assigned barn, unless necessary for use in another 159 
barn, in which case they were disinfected before and after use. 160 
 161 
Data collection 162 
Pen BW (Pen scale – scale head, Chore-Time 100, Milford IN; load cells, Tru Test MP 163 
800, Wellington, Auckland, New Zealand) and feed disappearance were determined at the start 164 
and end of the study, and used to calculate ADG, ADFI and G:F. Additionally, pigs in the HCh 165 
and LCh barns were individually tagged and weighed (Way Pig – Portable Litter Scale, 166 
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mechanical, Raytec Manufacturing, Ephrata, PA; Individual pig scale – scale head, Digi-Star 167 
stockweight 600, Fort Atkinson, WI; load cells) to assess BW variation at the start of the 168 
experiment and at the start of the marketing phase, i.e. at the first marketing group. Date and BW 169 
were recorded for any pigs removed from the study due to illness, injury or death. All pigs that 170 
started the experiment were accounted for as 1) pigs removed from the study due to morbidity, 2) 171 
mortality, 3) full value market pigs (pigs sent to a primary market) or 4) light-cull pigs (lights or 172 
cull pigs sent to a secondary market).  173 
Pigs were marketed in 3 separate groups based on BW to achieve a targeted harvest 174 
weight of 130 kg. Prior to marketing, all pigs were weighed and received slap tattoos on both 175 
hams identifying them according to barn and pen. Hot carcass weight, percent lean, percent 176 
yield, back-fat depth and loin depth were collected at the harvest facilities (JBS, Marshalltown, 177 
IA). Research personnel attended the harvest to confirm data accuracy.  178 
Oral fluid samples were collected from six randomly selected pens within each barn on d 179 
7, 63 and 105 to assess the HC over the duration of the experiment. In a method described by 180 
Prickett et al. (2008), oral fluid samples were collected by hanging a cotton rope in the pen for 181 
approximately 30 minutes. Prior to contact with ropes, new gloves were worn to ensure samples 182 
were not contaminated. Oral fluid was harvested from the rope by placing the wet end of the rope 183 
into a new plastic bag, wringing out the rope and then transferring the oral fluid to a centrifuge 184 
tube. Oral fluid was transported on ice, centrifuged for 10 minutes at 1,000 RPM and frozen at    185 
-80oC. Samples were analyzed by PCR for PRRSV and IAV-S at the Iowa State University 186 





Calculations  190 
Market BW was the average BW of the pigs marketed within a pen, while final BW was 191 
the average BW of all pigs at the end of the experiment including marketed pigs and light-cull 192 
pigs. 193 
Carcass ADG was calculated as [(final BW × yield) – (start BW × yield)] ÷ pig days. The 194 
observed average yield of 73% at harvest was also applied to the start weight. Carcass G:F was 195 
calculated as carcass ADG ÷ ADFI.  196 
 197 
Economic analysis  198 
Growth performance, pig fate and carcass data obtained from this experiment were 199 
applied to a modelled 2,400 pig grow-finish pig barn, which is a typical of the U.S. pork 200 
industry. Start BW, d on feed, d to market, ADFI, mortality, percentage of market pigs sold, 201 
percentage of light-cull pigs sold and carcass yield were utilized in the economic model. For the 202 
purposes of the economic analysis, ADG for only full value market pigs was used. Start BW was 203 
standardized to 13.1 kg for both economic models. In the fixed-time model, carcass yield was 204 
standardized at 73%.  205 
Similar to other published reports on the economic impact of swine diseases, a swine- 206 
enterprise budgeting model was developed to specify the mathematical relationships between 207 
production inputs and outputs, as well as costs and revenues associated with swine production 208 
(Holtkamp et al., 2013; Schulz and Tonsor, 2015). Two grow-finish models were employed: 1) 209 
assuming pigs are marketed at a fixed BW of 130 kg and referred to as the fixed-weight model, 210 
and 2) assuming pigs are harvested after a fixed time of 133 d in the barn, referred to as the 211 
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fixed-time model. Both models exist in commercial practice. Within each model, returns were 212 
calculated on a per pig sold and per pig placed basis.  213 
The economic analysis was conducted, and reported in, US dollars in all instances. 214 
Production costs were obtained from data compiled by Meta Farms (MetaFarms, Burnsville, 215 
MN), USDA-AMS, and Iowa State University (Ames, IA) in 2015 (Table 3.1). The price per 216 
feeder pig was calculated by using the composite weighted average price (formula and cash) of 217 
an 18 kg feeder pig from the National Direct Delivered Feeder Pig Report NW_LS255. The 218 
feeder pig price ($55.51 per pig) was based on an average of weekly prices reported during 2015 219 
(USDA-AMS, 2017a). However, the feeder pigs in this study were lighter at 13 kg. In order to 220 
appropriately apply a feeder pig price, a linear relationship was used between price and weight. 221 
The feeder pig price used in this model was $41.63 per pig. Feed costs were applied based on the 222 
feed budget assigned per feeding phase. Major ingredient prices were calculated from the North 223 
Central Iowa corn prices report NW_GR110, Iowa DDGS report NW_GR111 and Iowa SBM 224 
report NW_GR116 (USDA-AMS, 2017b,c,d). Other ingredient prices were obtained from Meta 225 
Farms. Based on a weighted average of ingredient prices, diet costs across phases were 226 
calculated to be $201.67/t. Transportation costs were obtained from the Iowa State University Ag 227 
Decision Maker website ($3.90/loaded mile, semi-trailer; Plastina and Johanns, 2015). Assuming 228 
a semi-trailer capacity of 500 feeder pigs, and transportation distance of 25 miles, the cost of 229 
transportation for feeder pigs used in this model is $0.195 per pig placed. Assuming truck 230 
capacity of 130 market pigs and a distance to market of 50 miles, the cost of transportation for 231 
market pigs used in this model was $1.50 per market pig. A base price for veterinary costs 232 
($5.00/pig placed) was obtained from Meta Farms and was applied to the LCh barn. The MCh 233 
and HCh barns incurred additional veterinary costs of $2.37 and $2.02/pig sold, respectively. 234 
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These added costs were due to the increased number of pig treatments in these barns and the 235 
medications used related to different clinical symptoms. An assumed yardage cost ($0.115/pig 236 
space/day) was obtained from Meta Farms. Yardage costs can be a major component of the total 237 
costs of pork production, and vary significantly from one producer to the next. Yardage is 238 
broadly defined as overhead costs, and incorporates non-feed costs that are not associated with 239 
hog ownership. Yardage calculations will vary and costs included differ; nonetheless, the 240 
assumed yardage cost used in this model included fuel, operating interest, machinery, labor and 241 
building depreciation, taxes and insurance. The secondary market price of lightweight and cull 242 
pigs ($78.74/pig) was obtained from Meta Farms. The primary market hog price was calculated 243 
by using the average of the monthly negotiated Iowa/Minnesota Daily Direct Prior Day Hog 244 
Report LM_HG 204 (plant delivered) prices for 2015 ($1.48/kg CW; USDA-AMS, 2017e). 245 
 Total revenue was calculated based on income generated by marketing pigs to both a 246 
primary market and secondary market for light-cull pigs. Profit was determined after total costs 247 
were subtracted from total revenue and reported for the entire barn on a per pig marketed and per 248 
pig placed basis. These values were compared across treatment to estimate losses due to a HC, 249 
relative to the LCh treatment. 250 
The sensitivity of these results to changes in the price of feeder pigs, market hogs (both 251 
full value and lightweight culls), and feed costs was also explored to provide some appreciation 252 
for the extent to which prices and costs impact the magnitude of production losses and decreased 253 
productivity on net returns. In addition to the baseline models, alternative scenarios were created 254 
by increasing or decreasing feeder pig and market hog prices and feed costs by 20% while 255 




Statistical analysis  258 
PROC UNIVARIATE (SAS Inst., Inc., Cary, NC) was used to determine equality of 259 
variances and to remove outliers, which were defined as observations beyond 3 standard 260 
deviations of the mean. Pig growth and carcass data were analyzed using MIXED model 261 
methods (SAS Inst., Inc., Cary, NC) with pen as the experimental unit, HC and sex as fixed 262 
effects and start BW as linear covariate. Pig fate data were analyzed using the binary distribution 263 
in GLIMMIX model methods (SAS Inst., Inc., Cary, NC) with pen as the experimental unit, HC 264 
and sex as fixed effects and start BW as a linear covariate. PRRSV genomic copies in oral fluid 265 
samples were analyzed using the MIXED model methods (SAS Inst., Inc., Cary, NC) with pen as 266 
the experimental unit, HC as the fixed effect and d as the repeated measure. Statistical 267 
significance was determined at P ≤ 0.05 and trends considered when 0.05 < P ≤ 0.10.  268 
 Pen within barn was used as the experimental unit, with HC being the observed treatment 269 
(n = 36). The authors recognize that in most animal science research, the barn would be 270 
considered the experimental unit. However, it is not possible to replicate a disease treatment 271 
across multiple barns; as demonstrated in this study, health status within a barn can change over 272 
time, making replication improbable. However, great care was taken to ensure that any potential 273 
differences among the barns other than disease were minimized; as previously explained, the 3 274 
barns were identical in design and construction, were all managed by the same person, were of 275 
the same genetic origin and received the same dietary regime. All 3 barns were located on the 276 
same site to eliminate the chance of differences in weather affecting outcomes. On this basis, it 277 
was concluded that the pen within the barn can be considered the experimental unit, although the 278 
chance of other factors besides HC affecting performance cannot be completed precluded. This 279 
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experimental design is similar to other health or disease research published previously including 280 
but not limited to Schweer et al. (2016a,b), Rochell et al. (2015), and Che et al. (2015).  281 
 282 
Results 283 
Characterization of the health challenge 284 
All barns showed clinical PRRSV symptoms including lethargy, mortality and reductions 285 
in gain. Oral fluid PCR evaluation revealed that they had all experienced a PRRSV infection 286 
(Table 3.2). The HCh treatment had the greatest oral fluid PRRSV genomic copy concentration 287 
at d 7 and 63; however, at d 105, the MCh had the greatest concentration (Fig. 3.1). The HCh 288 
treatment was suspected of being infected with a secondary PRRSV strain, based on diagnostic 289 
testing results. However, due to the virus’s ability to mutate quickly, it is uncertain whether a 290 
second PRRSV detection was a mutation or a second lateral virus introduction into the 291 
environment from a different source. Oral fluid PCR results showed that the MCh treatment 292 
contracted IAV-S (H1N2) by d 7 and both HCh and MCh treatments were diagnosed with IAV-S 293 
(H1N1) on d 63. Additionally, clinical symptoms of IAV-S were observed in the HCh and MCh 294 
treatments including anorexia, lethargy, labored breathing and coughing. As HC increased, the 295 
number of treatments with injectable medications were elevated (1,108, 2,335 and 3,415 in the 296 
LCh, MCh and HCh treatment, respectively). 297 
Increasing HC reduced the percentage of pigs sold as full-value pigs and also increased 298 
mortality (P < 0.001; Table 3.3). There was a trend for an increased percentage of pigs removed 299 
from the experiment due to illness and/or injury as HC increased (P = 0.079). A trend was also 300 
observed for the percentage of pigs sold as light-culls to increase with increasing HC (P = 301 
0.061).  302 
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Effect of health challenge on growth performance 303 
As the HC increased, ADG decreased; furthermore, ADFI and G:F were poorer in MCh 304 
and HCh compared to LCh (P < 0.001; Table 3.4). Starting and ending BW CV were greater in 305 
HCh compared with LCh (P < 0.001). Similar to whole body ADG, carcass ADG decreased as 306 
the HC increased in severity (P < 0.001). Much like whole body G:F, the carcass G:F was 307 
greatest in the LCh treatment but similar in the MCh and HCh treatments (P < 0.001).  308 
 Barrows had greater final BW (P < 0.001), ADG (P < 0.001) and ADFI (P < 0.001) when 309 
compared to gilt, with mixed pens intermediate between the two. Gilts were more efficient than 310 
barrows, again with mixed pens intermediate (P < 0.001). No sex differences were observed for 311 
starting or ending BW CV (P > 0.10). Similar to whole body ADG, carcass ADG was greatest 312 
for the barrows and least for the gilts, with mixed pens intermediate (P = 0.011). Carcass 313 
efficiency was greater in the gilt pens and mixed pens when compared to the barrow pens (P < 314 
0.001).   315 
 316 
Effect of health challenge on carcass characteristics  317 
  Days to market increased as HC increased (P < 0.001, Table 3.5). The MCh and HCh 318 
treatments had greater market BW and HCW (P < 0.001) than the LCh treatment. Carcass yield 319 
was greatest in MCh compared to HCh, which in turn was greater than LCh (P < 0.001). There 320 
were no differences among treatments for loin depth, fat depth or estimated lean yield (P > 0.10).  321 
 Compared to gilts, barrows were heavier at market when expressed as Market weight 322 
(P=0.01) or hot carcass weight (P < 0.001); the mixed sex pens were intermediate between the 323 
two. Gilts had less backfat and greater lean yield than barrows, with mixed sex pens 324 
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intermediate. No differences were observed among sexes for carcass yield or loin depth (P > 325 
0.10).  326 
 327 
Effect of heath challenge on net returns 328 
In the fixed-weight model, increasing HC resulted in total barn losses of $21,454 and 329 
$46,199 for MCh and HCh, respectively, compared to LCh (Table 3.6). Comparing HCh with 330 
MCh, net profits were reduced by $24,746. Reductions in the sale of full value pigs and lower 331 
carcass weight were the main contributors to lost revenue. Costs were increased from LCh to 332 
MCh but reduced in the HCh, as a result of differences in days to market, affecting yardage 333 
costs, as well as the cost of individual pig medical treatments. The much higher mortality in HCh 334 
resulted in lower feed costs compared to LCh and MCh, because fewer pigs were fed to market; 335 
transportation costs were affected in the same way. Due to the impacts on both revenues and 336 
expenses, net profit per pig marketed was reduced from LCh to MCh to HCh ($15.16, $5.70 and 337 
($8.11), respectively). Reductions in net profit were also observed when expressed on a per pig 338 
placed basis: $13.53, $4.59 and ($5.72), for LCh, MCh and HCh, respectively.  339 
Sensitivity analysis helps to place changes in net income in the context of fluctuations in 340 
market hog prices and feed costs; Table 3.7 presents the results of such sensitivity analysis when 341 
market hog prices and/or feed prices fluctuated 20% above or below average.  These results 342 
show the increase in losses in MCh and HCh, compared to LCh. It can be seen that in the fixed 343 
weight model, losses in MCh compared with LCh would range from $8.49/pig to 10.44/pig. 344 
Similarly, losses in HCh would range from $20.44 to $26.10 when compared to LCh.  345 
In the fixed-time model, increasing HC resulted in total barn losses of $27,638 and 346 
$49,820 for MCh and HCh, respectively, compared to LCh (Table 3.8). Comparing HCh with 347 
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MCh, net profits were reduced by $22,182; in this way, it can be seen that losses due to HC are 348 
magnified in the fixed-time as compared to the fixed-weight model. Due to the impacts on both 349 
revenues and expenses, net profit per pig marketed was reduced from LCh to MCh to HCh 350 
($15.70, $3.09 and ($9.56) USD, respectively). Reductions in net profit were also observed when 351 
expressed on a per pig placed basis: $14.01, $2.49 and ($6.75) USD, for LCh, MCh and HCh, 352 
respectively. 353 
The sensitivity of these results to changes in market prices and feed costs are presented in 354 
Table 3.9. The financial loss due to an increased HC from LCh to MCh ranged between $11.02 355 
and $14.20 USD/pig marketed. From LCh to HCh, the range in losses per pig marketed was 356 
$20.71 to $29.82. Thus, market conditions affect the financial impact of an increased HC. 357 
 358 
Discussion  359 
The range of impact on performance and net returns relative to the severity of naturally 360 
occurring, multi-etiology disease under commercial conditions is not well documented. Exposure 361 
to PRRSV and IAV-S will cause lethargy, reduced growth rates and increase mortality and 362 
morbidity (Rochell et al., 2015; Schweer, 2015; Schweer et al., 2016a). Exacerbated symptoms 363 
in the event of multiple infections is expected; however, very little data exist to confirm this and 364 
quantify its impact. Van Reeth et al. (1996) reported intensified clinical symptoms in the event of 365 
a PRRSV co-challenge with IAV-S or porcine respiratory coronavirus (PRCV) in feeder pigs. 366 
Van Reeth et al. (1996) reported that observed clinical symptoms were variable in different 367 
groups of pigs challenged with the same PRRSV-IAV-S combination, demonstrating that co- 368 
challenges are difficult to reproduce and will impact pigs differently than an infection with a 369 
single virus. Much like Van Reeth’s experiment, pigs in this study had exacerbated clinical 370 
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symptoms in the MCh and HCh treatments due to the PRRSV and IAV-S co-challenge but the 371 
HCh was more severely impacted than the MCh.  372 
Due to the increased HC, individual pigs treated with injectable medications was 373 
increased by 53% and 68% in the MCh and HCh treatments, respectively, compared to LCh. 374 
Increasing HC resulted in increased mortality by 57% and 83% in the MCh and HCh treatments, 375 
respectively. The mortality observed in the present study was greater than expected based on the 376 
current literature. In an economic analysis by Holtkamp et al. (2013) greater severity of a 377 
PRRSV infection increased mortality by as much as 35%.  378 
In the present study, due to increased mortality, the proportion of animals sold as full 379 
value pigs decreased by 10% and 21% in the MCh and HCh, respectively, which again is greater 380 
than that reported by Holtkamp et al. (2013). They reported a 0.73% and 0.62% decrease in full 381 
value pigs sold in the event of a PRRSV challenge. The study reported herein characterized the 382 
relative health status of the three barns but did not comprehensively diagnose all potential 383 
pathogens in the three barns. To test for all potential pathogens would have been cost prohibitive 384 
and, as some definitive tests require post-mortem samples, would have interfered with growth 385 
and performance data of the pigs. Thus, knowing absolute health status comprehensively and 386 
collecting performance data with minimal iatrogenic manipulation is very challenging. One of 387 
the explanations for variance from the numbers reported by Holtkamp et al. (2013) and those 388 
measured here could be the undetected presence of additional pathogens in this study that were 389 
not modeled in the Holtkamp study.      390 
In the event of a health challenge, it is well understood that growth performance will be 391 
influenced due to a reductions in feed intake, muscle protein catabolism and diverting necessary 392 
nutrients to support immune function (Williams 1997a,b,c; Huntley et al., 2017). Van Reeth et al. 393 
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(1996) reported pigs had reduced ADG under a PRRSV-IAV-S challenge; however, to the 394 
authors knowledge no other data exist that describes the impact of a PRRSV and IAV-S co- 395 
infection specifically on growth performance in grow-finish pigs. Rochell et al. (2015) and 396 
Schweer et al. (2015; 2016a) reported reduced overall ADG and ADFI when pigs were under a 397 
PRRSV challenge. While ADG and ADFI were lower in the present experiment, the modest 398 
reduction in G:F was a surprise. In a grow-finish experiment by Schweer et al. (2015), feed 399 
efficiency was reduced by 6.8% when pigs experienced a PRRSV infection, which is greater than 400 
the 4.8% observed in this experiment.  401 
There were no differences observed in final BW; this was expected as pigs from all 402 
treatments were marketed on the basis of BW and not on the basis of time in the barn. Due to 403 
suppressed growth rates, days to market was lengthened by 10 and 15 d in the MCh and HCh, 404 
respectively, compared to LCh. Schweer et al. (2015) reported 14 greater days to market when 405 
pigs experienced a PRRSV infection.  406 
The design of this experiment dictated that pigs were marketed at a similar BW, to 407 
provide the best comparison for the HC effects on carcass composition. It would be expected that 408 
the slower growing pigs would tend to be leaner and would deposit less fat (Williams et al., 409 
1997c; Schweer et al., 2015); however, this was not observed in the present experiment.  410 
Using parameters for growth, mortality and full value pigs sold, Neumann et al. (2005) 411 
first assessed the financial burden of PRRSV on U.S. pig producers as $494 USD million in 412 
grow-finish pigs. Later, Holtkamp et al. (2013) estimated these losses at $664 USD million in 413 
grow-finish pigs. In a recent interim report, Holtkamp reported that the economic impact of 414 
PRRSV has fallen by $83 million USD to $581 million USD in grow-finish pigs (Miller, 2017). 415 
Both economic models in the present study reveal serious losses in the event of a PRRSV and 416 
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IAV-S co-challenge under commercial conditions; however, the fixed-time model resulted in 417 
greater losses when calculated on a per barn-turn basis. Neumann et al. (2005) estimated PRRSV 418 
cost U.S. hog producers $7.67 USD/pig, while Holtkamp et al. (2013) reported production losses 419 
of $4.67 USD for every pig marketed in the U.S. Unfortunately, these economic analyses by 420 
Neumann and Holtkamp only assess the economic contribution of a PRRSV infection. They also 421 
represent “average” losses estimated across the total US pig herd. The results of this experiment 422 
suggest that the economic impact of a co-challenge can vary widely.   423 
In conclusion, increasing severity of health challenge reduced ADG by 8% and 14% in 424 
this experiment and resulted in mortality as high as 19.9%. Losses of $9.47 to $25.27 USD/pig 425 
marketed underscores the potential magnitude of the economic impact of mixed etiology 426 
concurrent diseases.    427 
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Table 3.1. Parameter values used to determine revenues and expenses in a study 
estimating the economic impact of an increased health challenge (HC) in grow-finish pigs 
raised under commercial conditions1 
Parameter Value7 
Expenses 
 Feed Cost2 ($/t) 201.67 
 Feeder pig costs3 ($/pig placed) 41.63 
 Veterinary costs2,4 ($/pig placed) 5.00 
 Placement transportation costs5 ($/pig placed) 0.195 
 Market transportation costs5 ($/pig marketed) 1.50 
 Yardage cost2 ($/pig space/day) 0.115 
Revenue 
 Full value pigs5 ($/kg CW) 1.48 
 Secondary market pigs2 ($/head) 73.29 
1Three 1,000 pig grow-finish facilities, located on the same production site in Iowa, were 
each populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 
terminal sire], this study did not start until approximately 34 d post weaning (13.1 ± 0.2 
kg of BW). Pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2North Central Iowa corn prices report NW_GR110, Iowa DDGS report NW_GR111 and 
Iowa SBM report NW_GR116 (USDA-AMS 2017b,c,d) 
3Feeder pig national report LM_LS255 (USDA-AMS, 2017a) 
4Added costs associated with increased health challenge were $2.37 and $2.02 per pig 
sold for   MCh and HCh, respectively  
5Iowa State Ag decision maker (Plastina and Johanns, 2015) 
6Iowa/Minnesota Daily Direct Prior Day Hog Report LM_HG 204 (USDA-AMS, 2017e) 
























Table 3.2. Number of positive diagnostic evaluations on oral fluid for porcine 
reproductive and respiratory syndrome virus (PRRSV) and influenza type A virus of 
swine (IAV-S) by PCR at d 7, 63 and 105 in grow-finish pigs raised under commercial 
conditions1 
Item LCh MCh HCh 
PRRSV     
 d 7  6/6 6/6 6/6 
 d 63 6/6 6/6 6/6 
 d 105 0/6 5/6 1/6 
IAV-S     
 d 7  0/6 5/6 H1N2 0/6 
 d 63 0/6 6/6 H1N1 6/6 H1N1 
 d 105 0/6 0/6 0/6 
Low challenge health (LCh), moderate challenge health (MCh), high challenge health 
(HCh) 
1 Three 1,000 pig grow-finish facilities, located on the same production site in Iowa, were 
each populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 
terminal sire], this study did not start until approximately 34 d post weaning (13.1 ± 0.2 
































Table 3.3. The effect of three health challenges (HC) and sex on pig fate in grow-finish 
pigs raised under commercial conditions1 
Item 
Health Challenge3 Sex4 Pooled 
SEM 
P-value2 
LCh MCh HCh Barrows Mixed Gilts HC Sex 
No. pens 36 30 36 44 12 46    
No. pigs 911 756 885 1095 304 1153    
Full-value5, % 89.2a 80.5b 70.6c 80.1 83.4 80.2 2.6 < 0.001 0.496 
Light-cull5, % 4.2 6.9 3.2 3.9 4.4 5.6 1.4 0.061 0.168 
Mortality5, % 3.3a 7.7b 19.9c 10.1 6.4 8.3 1.9 < 0.001 0.181 
Morbidity5, % 3.1 5.0 6.5 5.0 4.6 4.4 1.4 0.079 0.836 
a-c or z-x within a row, least square means lacking a common superscript differ, P < 0.05 
Low challenge health (LCh), moderate challenge health (MCh), high challenge health 
(HCh) 
1 Three 1,000 pig grow-finish facilities, located on the same production site in Iowa, were 
each populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 
terminal sire], this study did not start until approximately 34 d post weaning (13.1 ± 0.2 
kg of BW). Pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2Probability values for main effects of HC or sex 
3Least square means of HC 
4Least square means of sex 





























Table 3.4. The effect of three health challenge (HC) and sex on whole body and carcass 
based growth performance in grow-finish pigs raised under commercial conditions1 
Item 
Health Challenge3 Sex4 Pooled 
SEM 
P-value2 
LCh MCh HCh Barrows Mixed Gilts HC Sex 
 Start BW, kg 13.3 13.7 12.4 13.0 13.1 13.2 0.2 < 0.001 0.186 
 Final BW5, kg 129.1 130.6 130.6 133.6z 130.5y 126.1x 1.4 0.354 < 0.001 
 Start BW CV, % 21.0a - 26.2b 23.7 23.6 23.6 1.0 < 0.001 0.984 
 End BW CV, % 12.2a - 15.5b 14.3 14.0 13.3 0.8 < 0.001 0.328 
 ADG5,6, kg 0.86a 0.79b 0.74c 0.82z 0.80zy 0.77y 0.01 < 0.001 < 0.001 
 ADFI5,6, kg 2.05a 2.00a 1.83b 2.06z 1.95y 1.85x 0.03 < 0.001 < 0.001 
 G:F5 0.42a 0.40b 0.40b 0.40x 0.41y 0.42z 0.004 < 0.001 < 0.001 
Carcass basis          
 ADG5,6, kg 0.61a 0.55b 0.50c 0.56z 0.56z 0.54y 0.01 < 0.001 0.004 
 G:F5 0.30a 0.28b 0.28b 0.27y 0.29z 0.29z 0.004 < 0.001 < 0.001 
a-c or z-x within a row, least square means lacking a common superscript differ, P < 0.05 
Low challenge health (LCh), moderate challenge health (MCh), high challenge health 
(HCh) 
1 Three 1,000 pig grow -finish facilities, located on the same production site in Iowa, 
were each populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 
terminal sire], this study did not start until approximately 34 d post weaning (13.1 ± 0.2 
kg of BW). Pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2Probability values for main effects of HC or sex 
3LS means of HC 
4LS means of sex 
5Average start body weight used as a covariate 

























Table 3.5. The effect of three health challenges (HC) and sex on carcass measurements in 
grow-finish pigs raised under commercial conditions1 
Item 
Health Challenge3 Sex4 Pooled 
SEM 
P-value2 
LCh MCh HCh Barrows Mixed Gilts HC Sex 
Days to Mkt.5,6 133a 143b 148c 141 141 141 0.2 < 0.001 0.085 
Market Wt.5, kg 129.3b 132.6a 132.6a 135.0z 132.0y 127.5x 1.3 0.010 < 0.001 
HCW5, kg 93.5b 98.2a 97.6a 99.0z 94.0y 93.7x 1.0 < 0.001 < 0.001 
Yield, % 72.4c 74.1a 73.6b 73.3 73.2 73.5 0.2 < 0.001 0.189 
Lean, % 55.1 54.8 54.8 53.4x 55.2y 56.4z 0.2 0.428 < 0.001 
Loin depth, mm 60.2 60.7 60.5 60.1 60.5 60.9 0.6 0.662 0.200 
Fat depth, mm 18.1 18.6 18.5 20.7z 18.4y 16.1x 0.3 0.235 < 0.001 
a-c or z-x within a row, least square means lacking a common superscript differ, P < 0.05 
Low challenge health (LCh), moderate challenge health (MCh), high challenge health 
(HCh) 
1 Three 1,000 pig grow-finish facilities, located on the same production site in Iowa, were 
each populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 
terminal sire], this study did not start until approximately 34 d post weaning (13.1 ± 0.2 
kg of BW). Pigs remained on test until achieving marketing BW (130.5 ± 1.4 kg) 
2Probability values for main effects of HC or sex 
3LS means of HC 
4LS means of sex 
5Average start body weight used as a covariate 



























Table 3.6. The calculated economic impact of an increasing health challenge (HC), 
assuming all pigs sold using a fixed-weight model, 130 kg 
Parameter  LCh11 MCh11 HCh11 
Production times     
 Days on feed1 138 152 165 
 Days to market2 133 143 148 
Production impact    
 Total pigs placed, pig 2,400 2,400 2,400 
 Total pigs marketed full value3, pig 2,141 1,932 1,694 
 Live weight produced4, kg 278,304.00 251,160.00 220,272.00 
 Carcass weight produced5, kg 201,881.72 186,059.33 162,164.25 
 Pigs sold secondary market6, pig 101 166 77 
Economic impact     
 Total revenue7, $  306,172.58 287,504.63 245,631.76 
 Total costs8, $ 273,712.57 276,498.39 259,371.08 
 Net profit9, $ 32,460.01 11,006.24 (13,739.32) 
 Profit/pig marketed, $ 15.16 5.70 (8.11) 
 Profit/pig placed, $ 13.53 4.59 (5.72) 
 Opportunity lost10, $ - 21,453.77 46,199.33 
 Loss/pig marketed10, $ - 9.47 23.27 
 Loss/pig placed10, $  - 8.94 19.25 
Low challenge health (LCh), moderate challenge health (MCh), high challenge health 
(HCh) 
1Days on feed = total pig days (including mortality and morbidity) ÷ total pigs marketed 
full value 
2Average days to market required to achieve the target end body weight  
3Total pigs marketed full value = total pigs placed - (mortality + morbidity + pigs sold to 
secondary market) 
4Live weight produced = total pigs marketed full value ´ 130 kg 
5Carcass weight produced = live weight produced ´ % yield  
6Pigs that were considered underweight or cull animals  
7Total revenue = (carcass weight produced ´ $/kg full value pig) + (pigs sold secondary 
market ´ $/pig secondary market) 
8Cost of feeder pig, yardage, veterinarian, trucking and feed 
9Net profit = total revenue – total costs 
10Comparison of the LCh to the MCh and HCh net profit loss for the total barn and per 
pig marketed and per pig placed 












Table 3.7. Sensitivity of loss/pig marketed to alternative commodity prices (sensitivity 
analysis) due to an increasing health challenge (HC), assuming all pigs sold using a 
fixed-weight model, 130 kg 
  Feed costs1 
Change   
in HC 
Feeder pig, primary 
and secondary 







20% price increase 10.44 9.62 8.79 
Baseline3 10.29 9.47 8.64 
20% price decline 10.14 9.32 8.49 
LCh to 
HCh 
20% price increase 21.96 21.20 20.44 
Baseline3 24.03 23.27 22.51 
20% price decline 26.10 25.34 24.58 
MCh to 
HCh 
20% price increase 11.52 11.59 11.65 
Baseline3 13.74 13.81 13.87 
20% price decline 15.96 16.02 16.09 
Low challenge health (LCh), moderate challenge health (MCh), high challenge health 
(HCh) 
1All currency in USD 
2Basline price for feed costs $201.67/t  
3Baseline price for feeder pigs $41.63/pig, primary market pigs $1.48/kg CW and 



















Table 3.8. The calculated economic impact of an increasing health challenge (HC), 
assuming all pigs sold using a fixed-time model, 133 d 
Parameter  LCh11 MCh11 HCh11 
Production times     
 Days on feed1 138 142 149 
 Days to market2 133 133 133 
Production impact    
 Total pigs placed, pig 2,400 2,400 2,400 
 Total pigs marketed full value3, pig 2,141 1,932 1,694 
 Live weight produced4, kg 277,476.59 24,0579.94 206,654.51 
 Carcass weight produced5, kg 202,557.91 175,623.36 150,857.79 
 Pigs sold secondary market6, pig 101 166 77 
Economic impact     
 Total revenue7, $  307,173.34 272,059.39 228,898.21 
 Total costs8, $ 273,558.28 266,082.02 245,103.21 
 Net profit9, $ 33,615.06 5,977.37 (16,205.00) 
 Profit/pig marketed, $ 15.70 3.09 (9.56) 
 Profit/pig placed, $ 14.01 2.49 (6.75) 
 Opportunity lost10, $ - 27,637.69 49,820.06 
 Loss/pig marketed10, $ - 12.61 25.27 
 Loss/pig placed10, $  - 11.52 20.76 
Low challenge health (LCh), moderate challenge health (MCh), high challenge health 
(HCh) 
1Days on feed = total pig days (including mortality and morbidity) ÷ total pigs marketed 
full value 
2Set days allowed for this model   
3Total pigs marketed full value = total pigs placed - (mortality + morbidity + pigs sold to 
secondary market) 
4Live weight produced = total pigs marketed full value ´ [13.1 kg + (ADG ´ 133 d)] 
5Carcass weight produced = live weight produced ´ % yield  
6Pigs that were considered underweight or cull animals  
7Total revenue = (carcass weight produced ´ $/kg full value pig) + (pigs sold secondary 
market ´ $/pig secondary market) 
8Cost of feeder pig, yardage, veterinarian, trucking and feed 
9Net profit = total revenue – total costs 
10Comparison of the LCh to the MCh and HCh net profit loss for the total barn and per 
pig marketed and per pig placed 













Table 3.9. Sensitivity of loss/pig marketed to alternative commodity prices (sensitivity 
analysis) due to an increasing health challenge (HC), assuming all pigs sold using a 
fixed-time model, 133 d 
  Feed costs1 
Change   
in HC 
Feeder pig, primary 
and secondary 







20% price increase 11.12 11.07 11.02 
Baseline3 12.66 12.61 12.56 
20% price decline 14.20 14.08 14.10 
LCh to 
HCh 
20% price increase 20.71 21.13 21.55 
Baseline3 24.85 25.27 25.69 
20% price decline 28.98 29.33 29.82 
MCh to 
HCh 
20% price increase 9.59 10.06 10.53 
Baseline3 12.19 12.66 13.13 
20% price decline 14.78 15.25 15.72 
Low challenge health (LCh), moderate challenge health (MCh), high challenge health 
(HCh) 
1All currency in USD 
2Basline price for feed costs $201.67/t  
3Baseline price for feeder pigs $41.63/pig, primary market pigs $1.48/kg CW and 






























Figure 3.1. Oral fluid porcine reproductive and respiratory syndrome virus (PRRSV) 
concentration for three health challenges (HC) at d 7, 63 and 105 in grow-finish pigs 
raised under commercial conditions1 
Low challenge health (LCh), moderate challenge health (MCh), high challenge health 
(HCh) 
1 Three 1,000 pig grow-finish facilities, located on the same production site in Iowa, were 
each populated with 936 crossbred pigs [Cambrough female (PIC 1050) x DNA600 
terminal sire], this study did not start until approximately 34 d post weaning (13.1 ± 0.2 





























































General Discussion  
In 2016, 63% of total U.S market hog sales originated in Iowa and the 
surrounding 6 states (USDA, 2017). The pig density in this area is the result of lower cost 
feed ingredients, nutrient management, excellent infrastructure such as packing plants, 
feed processors, and professional, technical and research services. However, it increases 
the risk of disease transmission among production units. In the event of a health 
challenge, growth performance will be influenced due to a reductions in feed intake, 
muscle protein catabolism and diverting nutrients to support immune function (Williams 
1997a,b,c; Huntley et al., 2017). Porcine reproductive and respiratory syndrome virus 
(PRRSV) is the costliest disease facing pig producers. Holtkamp et al. (2013) estimated 
annual losses of $664 million due to PRRSV. While there are no published data on the 
costs attributed to influenza type A virus of swine (IAV-S), it is considered to be an 
economically important disease due to reduced growth rates and increased morbidity. A 
mixed etiology health challenge can be more costly as a consequence of the 
compounding of disease symptoms (Zimmerman et al., 2012).  
Due to production losses caused by health challenges, a large portion of research 
is focused on ways to minimize this impact. Isoflavones found in soybeans have been 
studied for the potential to have a positive effect on disease (Greiner et al., 2001a,b; 
Barbosa et al., 2011). As a main component of swine diets in the Midwestern U.S., 





known for their antioxidant, anti-inflammatory, anti-viral, and anti-mutagenic properties 
(Greiner et al., 2001a; Miadoková et al., 2002; Valsecchi et al., 2008). Therefore, the 
overall objectives of this thesis were to assess the productivity and economic importance 
of naturally occurring health challenges (HC) and to investigate a possible role for higher 
levels of dietary SBM to mitigate losses resulting from a HC. 
In chapter 2, it was found that diets containing higher levels of SBM improved 
final BW and G:F in the event of the observed mixed etiology HC. In the moderate 
challenge health (MCh) experiment sera isoflavones were elevated in diets containing 
higher levels of SBM, which could explain the improvements in growth performance. 
However, it is not clear why this was not observed in the high challenge health (HCh) 
experiment. Work published by Greiner et al. (2001a,b) revealed genistein linearly 
reduced serum virus concentrations and increased gain and feed intake during times of 
high serum viral concentrations; daidzein improved pig growth during times of high 
viremia. Unfortunately, due to the diets containing inconsistent amino acid levels, some 
of which were estimated to be below requirement, it was not possible to relate animal 
performance to the proportion of SBM or synthetic AA in the diet. Thus, this objective 
was not accomplished. 
In a PRRSV-IAV-S co-challenge, Van Reeth et al. (1996) demonstrating that co-
challenges are difficult to reproduce and will impact pigs differently than an infection 
with a single virus. Much like Van Reeth’s experiment, in Chapter 3 the MCh and HCh 
treatments had exacerbated clinical symptoms due to the PRRSV and IAV-S co-
challenge but the HCh was more severely impacted. Reductions in ADG, ADFI, and G:F 





agreed with Schweer et al. (2015) who reported 14 greater days to market when pigs 
experienced a PRRSV infection due to a reduction in growth performance. The severity 
of symptoms observed in this experiment increased mortality and reduced pigs sold 
greater than the current literature would suggest (Holtkamp et al., 2013). The negative 
impact of the HC on pig performance and pig fate resulted in losses between $9.47 and 
$25.27 per pig marketed.  
In summary, production losses associated with a health challenge is obviously 
detrimental to a production system; however, the financial impact was clearly 
demonstrated and was much greater than previously reported.  
 
Recommendations for Future Research  
The objective of chapter 2 was not accomplished due to inconsistent dietary AA 
levels. Inconsistent results following the work by Greiner et al. (2001a,b) mean there is 
much yet to be understood about the mechanism of soy isoflavones in grow-finish pigs. 
Further research on this topic is required to fully understand the bioavailability and the 
mechanism by which soy isoflavones work. If isoflavones have the ability to work in an 
immunomodulatory manner in pigs, swine producers should feed higher levels of dietary 
SBM in the event of a health challenge.    
In chapter 3, mortality was as great as 19.9%. While this is on the extreme end of 
production losses, it demonstrated how mixed etiological health challenges influence 
performance and net returns. This work supports the need for continued research on 
disease prevention, management, and eradication, and for the identification of dietary 
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CALCULATING SID AMINO ACIDS 
 
The following examples will outline how to calculate SID % of amino acids, utilizing 
assayed total amino acids and the NRC SI digestibility of essential amino acids.  
Table 1. NRC (2012) ingredient digestibility of amino acids 
Digestibility, % Corn1 SBM2 DDGS3  DDG4  Lysine HCl Tryptophan Threonine MHA 
Lysine 74% 89% 61% 78% 100% - - - 
Methionine 83% 89% 82% 89% - - - 100% 
Cystine 80% 84% 73% 81% - - - - 
TSAA - - - - - - - - 
Isoleucine 82% 89% 76% 83% - - - - 
Threonine 77% 85% 71% 78% - - 100% - 
Tryptophan 80% 91% 71% 71% - 100% - - 
Valine 82% 87% 75% 81% - - - - 
1Yellow dent corn (pg 261 of NRC) 
2Solvent extracted soybean meal (pg 332 of NRC) 
3Corn DDGS >6 and <9% oil (pg 226 of NRC) 
4Corn DDG no soluble (pg 264 of NRC) 
 
Example 1: Phase 2, high soybean meal (HSBM) diet 
Pig weight:  27-41 kg  
SID lysine requirement (25-50 kg pigs): 0.98% (pg 210 NRC)  
Total assayed lysine: 1.34  
 
Step 1: Determine the lysine digestibility using the diet formulation and the NCR values 
for digestibility: 
 
Determine the ingredients that contribute lysine to the diet. Multiply the percentage of 





Add together the lysine digestibility contributed by each ingredient. This number is then 
divided by the total percentage of ingredients that contribute lysine to the diet.  
 
Corn: 36.50 × .74 = 27.01 
SBM: 37.91 × .89 = 33.74 
DDGS: 20.00 × .61 = 12.20 
Lysine HCL: 0.00 × 1.0 = 0.00  
            +______ 
   72.95  
 
72.95 ÷ (36.50 + 37.91 + 20.00 + 0.00) = 0.77 
 
Lysine digestibility = 0.77 
 
Step 2: Calculate the SID lysine: multiply the assayed total lysine 
(1.34) found in the diet by the digestibility calculated in step 1: 
 
1.34 × 0.77 = 1.04 SID % lysine  
 
Step 3: Does this meet requirement? Using the NRC values for amino acid requirements 
for 11-25 kg: 







Ingredient, % HSBM 
Corn  Ü 36.50 
SBM  Ü 37.91 





Copper Sulfate 0.05 
MXE 0.05 
Lysine HCl Ü 0.00 
MHA 0.00 
Threonine 0.00 
Color tracker9 0.00 
CTC 100 0.20 
Denagard 10 0.18 
Total  100.00 






Example 2: Phase 4, moderate synthetic amino acid (MSAA) diet 
Pig weight: 47-63 kg  
SID threonine requirement (50-75 kg): 0.52% (pg 210 NRC)  
Total assayed threonine: 0.75 
 
Step 1: Determine the SI digestibility: 
 
[(53.80 × .77) + (21.50 × .85) + (20.00 × .71) +(0.04 × 1.00)] ÷ 
    (53.80 + 21.50 + 20.00 + 0.04) = 0.78 
 
Threonine digestibility = 0.78 
 
Step 2: Calculate the SID threonine: 
 
0.75 × 0.78 = 0.59 SID % threonine  
 
Step 3: Does this meet requirement? Using the NRC values for amino acid requirements 
for 50-75 kg: 







Ingredient, % MSAA 
Corn  Ü 53.80 
SBM  Ü 21.50 









Lysine HCl  0.35 
MHA 0.00 
Threonine Ü 0.04 
Tryptophan 0.00 
Color tracker9 0.05 
Total  100.00 






Example 3: Phase 8, high synthetic AA (HSAA) diet 
 
Pig weight 110-130 kg  
SID tryptophan requirement (100-135 kg): 0.11% (pg 210 NRC)  
Total assayed tryptophan: 0.12 
 
Step 1: Determine the SI digestibility:  
 
[(74.30 × .80) + (1.00 × .91) + (0.03 × 1.00) +(20.00 × 0.71)] ÷ 
    (74.30 + 1.00 + 0.03 + 20.00) = 0.78 
 
Tryptophan digestibility = 0.78 
 
Step 2: Calculate the SID tryptophan: 
 
0.12 × 0.78 = 0.10 SID % tryptophan  
 
Step 3: Does this meet requirement? Using the NRC values for amino acid requirements 
for 50-75 kg: 
No, our diet does not meet requirement. Our diet has 0.10 SID % tryptophan, while the 




Ingredient, % HSAA 
Corn Ü 74.30 





Copper Sulfate 0.05 
MXE 0.05 
Lysine HCl 0.46 
Threonine  0.07 
Tryptophan Ü 0.03 
Color tracker9 0.05 
DDG Ü 20.00 
Total 100.00 







NRC. 2012. Nutrient requirements of swine. 11th rev. ed. Natl. Acad. Press. Washington, 
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